Details of the Drug Combination

General Information of Drug Combination (ID: DC7M4N9)

• Drug Combination Name: Simvastatin + Rosiglitazone
• Indication: Type-2 diabetes; Status: Phase 1 [1]
• Component Drugs:
  Simvastatin (DM30SGU): Small molecular drug
  Rosiglitazone (DMILWZR): N.A.

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Simvastatin

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[2]
Atherosclerosis	BD40	Approved	[2]
Coronary heart disease	BA80.Z	Approved	[2]
Cystic fibrosis	CA25	Approved	[2]
Depression	6A70-6A7Z	Approved	[2]
Hypercholesterolaemia	5C80.0	Approved	[3]
Hyperlipidemia	5C80.Z	Approved	[2]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[2]
Hypertriglyceridemia	5C80.1	Approved	[2]
Pneumonia	CA40	Approved	[2]
Primary hypercholesterolemia	5C80.00	Approved	[2]
Prostate carcinoma	N.A.	Approved	[2]
Rhinitis	FA20	Approved	[2]
Type-1/2 diabetes	5A10-5A11	Approved	[2]
Stroke	8B20	Investigative	[2]

Simvastatin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[7]

Simvastatin Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[10]

Simvastatin Interacts with 8 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[11]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[12]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[13]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[14]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[15]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[12]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Metabolism	[12]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Metabolism	[12]

Simvastatin Interacts with 264 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Activity	[16]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[17]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Affects Response To Substance	[18]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Increases Response To Substance	[19]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Transport	[20]
Stromelysin-1 (MMP3)	OTGBI74Z	MMP3_HUMAN	Increases ADR	[21]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Increases Response To Substance	[22]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Decreases Response To Substance	[23]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Decreases Activity	[20]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[24]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Increases Expression	[24]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Activity	[24]
Prostaglandin E synthase (PTGES)	OTB7YQFU	PTGES_HUMAN	Decreases Expression	[25]
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Decreases Expression	[25]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Decreases Activity	[25]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[25]
Advanced glycosylation end product-specific receptor (AGER)	OTPY0IH7	RAGE_HUMAN	Decreases Expression	[25]
CCN family member 1 (CCN1)	OTKJBEMD	CCN1_HUMAN	Decreases Expression	[4]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Decreases Expression	[4]
Cell division control protein 45 homolog (CDC45)	OT6NNLOD	CDC45_HUMAN	Decreases Expression	[4]
Integrin beta-like protein 1 (ITGBL1)	OTJDHE17	ITGBL_HUMAN	Decreases Expression	[4]
Protein S100-A8 (S100A8)	OTVMOB3F	S10A8_HUMAN	Increases Expression	[4]
Integrin beta-1 (ITGB1)	OT6G1IAR	ITB1_HUMAN	Decreases Expression	[4]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Decreases Expression	[4]
Protein S100-A9 (S100A9)	OTOARHCS	S10A9_HUMAN	Increases Expression	[4]
Protein S100-A6 (S100A6)	OTHHPZQ8	S10A6_HUMAN	Increases Expression	[4]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Decreases Expression	[4]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Increases Expression	[4]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[4]
Annexin A3 (ANXA3)	OTDD8OI7	ANXA3_HUMAN	Decreases Expression	[4]
Keratin, type I cytoskeletal 13 (KRT13)	OTTYSKGX	K1C13_HUMAN	Increases Expression	[4]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2)	OTGVC9MY	PLCG2_HUMAN	Increases Expression	[4]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[4]
Keratin, type I cytoskeletal 15 (KRT15)	OTS6WLF7	K1C15_HUMAN	Increases Expression	[4]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[4]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[4]
Insulin-like growth factor-binding protein 6 (IGFBP6)	OTW878VI	IBP6_HUMAN	Increases Expression	[4]
Calmodulin-like protein 3 (CALML3)	OTM8DNQU	CALL3_HUMAN	Increases Expression	[4]
Gap junction beta-2 protein (GJB2)	OTBKLEYB	CXB2_HUMAN	Increases Expression	[4]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Decreases Expression	[4]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Increases Expression	[4]
DNA replication licensing factor MCM4 (MCM4)	OT19PNNG	MCM4_HUMAN	Decreases Expression	[4]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[4]
Macrophage metalloelastase (MMP12)	OT9Z7LHM	MMP12_HUMAN	Increases Expression	[4]
Replication factor C subunit 5 (RFC5)	OTAD79RT	RFC5_HUMAN	Decreases Expression	[4]
Regulator of G-protein signaling 2 (RGS2)	OT0FSRW7	RGS2_HUMAN	Increases Expression	[4]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Increases Expression	[4]
DNA primase small subunit (PRIM1)	OTWWP8Y6	PRI1_HUMAN	Decreases Expression	[4]
Cyclin-dependent kinase inhibitor 1C (CDKN1C)	OTASTJ3Q	CDN1C_HUMAN	Increases Expression	[4]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Decreases Expression	[4]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Increases Expression	[4]
Keratin, type I cytoskeletal 17 (KRT17)	OT6Y1DPK	K1C17_HUMAN	Increases Expression	[4]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Increases Expression	[4]
Focal adhesion kinase 1 (PTK2)	OT3Q1JDY	FAK1_HUMAN	Decreases Activity	[4]
Lymphotoxin-beta (LTB)	OTUFS8CF	TNFC_HUMAN	Decreases Expression	[4]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)	OT4SO7J4	BNIP3_HUMAN	Increases Expression	[4]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)	OTXNGZCG	MD2L1_HUMAN	Decreases Expression	[4]
Centromere protein R (ITGB3BP)	OT6Q7GR3	CENPR_HUMAN	Decreases Expression	[4]
Rho GTPase-activating protein 29 (ARHGAP29)	OT8JH4TY	RHG29_HUMAN	Decreases Expression	[4]
Interleukin-20 receptor subunit beta (IL20RB)	OTHFXK95	I20RB_HUMAN	Increases Expression	[4]
Bcl-2-binding component 3, isoforms 3/4 (BBC3)	OTUAXDAY	BBC3B_HUMAN	Increases Expression	[4]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Increases Expression	[4]
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1)	OTYRXD2T	PMYT1_HUMAN	Decreases Expression	[4]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Decreases Expression	[4]
Spondin-2 (SPON2)	OTE7JLNM	SPON2_HUMAN	Increases Expression	[4]
Rac GTPase-activating protein 1 (RACGAP1)	OTQE8IEH	RGAP1_HUMAN	Decreases Expression	[4]
DNA replication factor Cdt1 (CDT1)	OTVY53VG	CDT1_HUMAN	Decreases Expression	[4]
Matrix metalloproteinase-28 (MMP28)	OTHQZXM1	MMP28_HUMAN	Increases Expression	[4]
Alpha-catulin (CTNNAL1)	OTESJ6JD	CTNL1_HUMAN	Decreases Expression	[4]
Protein DBF4 homolog A (DBF4)	OTBL7JHQ	DBF4A_HUMAN	Decreases Expression	[4]
Krueppel-like factor 2 (KLF2)	OTIP1UFX	KLF2_HUMAN	Increases Expression	[4]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Activity	[26]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Localization	[27]
NPC1-like intracellular cholesterol transporter 1 (NPC1L1)	OT6GWW1P	NPCL1_HUMAN	Decreases Expression	[28]
Signal transducer CD24 (CD24)	OT7CODJ4	CD24_HUMAN	Increases Expression	[29]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Decreases Expression	[29]
Killer cell immunoglobulin-like receptor 2DS2 (KIR2DS2)	OTX31RLZ	KI2S2_HUMAN	Decreases Expression	[29]
Killer cell lectin-like receptor subfamily F member 1 (KLRF1)	OTGHZ7FU	KLRF1_HUMAN	Decreases Expression	[29]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)	OTLF4ZB1	IKKA_HUMAN	Increases Phosphorylation	[30]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Nitrosation	[30]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Phosphorylation	[30]
Methylenetetrahydrofolate reductase (MTHFR)	OTUBJSR7	MTHR_HUMAN	Increases Expression	[31]
Sphingosine 1-phosphate receptor 1 (S1PR1)	OTLTXDQT	S1PR1_HUMAN	Increases Expression	[32]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[33]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[34]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Decreases Secretion	[35]
Delta(24)-sterol reductase (DHCR24)	OTP301JW	DHC24_HUMAN	Increases Expression	[36]
Farnesyl pyrophosphate synthase (FDPS)	OT6CKWV5	FPPS_HUMAN	Increases Expression	[37]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Increases Expression	[37]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[38]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Expression	[38]
Toll-like receptor 4 (TLR4)	OTP7ML3S	TLR4_HUMAN	Increases Expression	[39]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B)	OTQ4W7MT	TR11B_HUMAN	Increases Expression	[40]
Dynamin-1-like protein (DNM1L)	OTXK1Q1G	DNM1L_HUMAN	Increases Expression	[41]
Suppressor of cytokine signaling 7 (SOCS7)	OT503VJG	SOCS7_HUMAN	Increases Expression	[42]
Suppressor of cytokine signaling 3 (SOCS3)	OTY183WJ	SOCS3_HUMAN	Increases Expression	[42]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Decreases Expression	[43]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[44]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Increases Expression	[45]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[46]
Serine protease HTRA2, mitochondrial (HTRA2)	OTC7616F	HTRA2_HUMAN	Affects Localization	[41]
Alpha-actinin-4 (ACTN4)	OTCNZAJ5	ACTN4_HUMAN	Increases Expression	[47]
E3 ubiquitin-protein ligase MARCHF6 (MARCHF6)	OTBTA03N	MARH6_HUMAN	Increases Degradation	[48]
Nephrin (NPHS1)	OT21JD3P	NPHN_HUMAN	Increases Expression	[47]
Toll-like receptor 2 (TLR2)	OTGO5P4R	TLR2_HUMAN	Increases Expression	[39]
Apolipoprotein M (APOM)	OTI3FQQC	APOM_HUMAN	Decreases Expression	[49]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Decreases Expression	[50]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Decreases Activity	[51]
Tissue-type plasminogen activator (PLAT)	OTQPDNAB	TPA_HUMAN	Increases Expression	[52]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Decreases Expression	[53]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Decreases Expression	[54]
GTPase KRas (KRAS)	OT78QCN8	RASK_HUMAN	Decreases Prenylation	[55]
Platelet-derived growth factor subunit B (PDGFB)	OTMFMFC3	PDGFB_HUMAN	Decreases Activity	[56]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Increases Expression	[57]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Activity	[58]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Increases Expression	[42]
Interleukin-2 receptor subunit alpha (IL2RA)	OT0MWCHG	IL2RA_HUMAN	Decreases Expression	[42]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Affects Expression	[59]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Decreases Expression	[60]
Collagen alpha-1(III) chain (COL3A1)	OTT1EMLM	CO3A1_HUMAN	Increases Expression	[61]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Increases Expression	[62]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[63]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Increases Expression	[64]
Transferrin receptor protein 1 (TFRC)	OT8ZPBDL	TFR1_HUMAN	Affects Expression	[39]
Osteocalcin (BGLAP)	OTK1YLWQ	OSTCN_HUMAN	Increases Expression	[65]
Interstitial collagenase (MMP1)	OTI4I2V1	MMP1_HUMAN	Decreases Secretion	[66]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Activity	[67]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Expression	[68]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[69]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[70]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Decreases Activity	[71]
Integrin beta-2 (ITGB2)	OTEKPEPR	ITB2_HUMAN	Decreases Expression	[72]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Increases Expression	[42]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Decreases Expression	[73]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Affects Expression	[74]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[75]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Decreases Expression	[76]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[72]
Transcription factor Jun (JUN)	OTCYBO6X	JUN_HUMAN	Decreases Localization	[77]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[78]
Thrombomodulin (THBD)	OT8VHLKY	TRBM_HUMAN	Increases Expression	[51]
Calpain-1 catalytic subunit (CAPN1)	OTK6OQZR	CAN1_HUMAN	Increases Expression	[79]
Heat shock protein HSP 90-alpha (HSP90AA1)	OTLG1WPK	HS90A_HUMAN	Increases Expression	[80]
Insulin-like growth factor 1 receptor (IGF1R)	OTXJIF13	IGF1R_HUMAN	Decreases Expression	[81]
Rho-related GTP-binding protein RhoC (RHOC)	OTOLE1FT	RHOC_HUMAN	Increases Expression	[51]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Decreases Activity	[82]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Increases Expression	[83]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[84]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[41]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[75]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[85]
Osteopontin (SPP1)	OTJGC23Y	OSTP_HUMAN	Decreases Expression	[86]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Affects Expression	[87]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Increases Expression	[79]
Cholesteryl ester transfer protein (CETP)	OTAGPPOE	CETP_HUMAN	Decreases Expression	[88]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Decreases Expression	[89]
Bone morphogenetic protein 2 (BMP2)	OT23T37S	BMP2_HUMAN	Increases Expression	[90]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[75]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Decreases Expression	[91]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Decreases Expression	[92]
HLA class I histocompatibility antigen, alpha chain E (HLA-E)	OTX1CTFB	HLAE_HUMAN	Affects Expression	[59]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Activity	[93]
Indoleamine 2,3-dioxygenase 1 (IDO1)	OT91DBN7	I23O1_HUMAN	Increases Expression	[94]
Ras-related C3 botulinum toxin substrate 2 (RAC2)	OTAOHFNH	RAC2_HUMAN	Affects Localization	[41]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Decreases Expression	[69]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Phosphorylation	[95]
Integrin beta-4 (ITGB4)	OT28UK84	ITB4_HUMAN	Increases Expression	[51]
Cytotoxic T-lymphocyte protein 4 (CTLA4)	OTYQR611	CTLA4_HUMAN	Decreases Expression	[42]
E-selectin (SELE)	OT33RZWY	LYAM2_HUMAN	Decreases Expression	[96]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP)	OT0DH40W	AL5AP_HUMAN	Increases Expression	[61]
Integrin alpha-L (ITGAL)	OTCUQAIS	ITAL_HUMAN	Decreases Expression	[72]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Expression	[94]
Tumor necrosis factor ligand superfamily member 4 (TNFSF4)	OTOCBX7P	TNFL4_HUMAN	Decreases Expression	[97]
Interleukin-4 receptor subunit alpha (IL4R)	OTTXOTCW	IL4RA_HUMAN	Decreases Expression	[42]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[89]
Tumor necrosis factor receptor superfamily member 5 (CD40)	OT5YU2XB	TNR5_HUMAN	Decreases Expression	[39]
CD27 antigen (CD27)	OTH7NA58	CD27_HUMAN	Decreases Expression	[42]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Increases Expression	[98]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Activity	[67]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Activity	[67]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Increases Expression	[99]
M-phase inducer phosphatase 2 (CDC25B)	OT12MSRY	MPIP2_HUMAN	Affects Expression	[100]
HLA class I histocompatibility antigen, alpha chain F (HLA-F)	OT76CM19	HLAF_HUMAN	Affects Expression	[59]
Type-1 angiotensin II receptor (AGTR1)	OT2NRMJP	AGTR1_HUMAN	Decreases Expression	[101]
Sodium-dependent serotonin transporter (SLC6A4)	OT6FGDLW	SC6A4_HUMAN	Increases Activity	[102]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[103]
Heat shock 70 kDa protein 4 (HSPA4)	OT5HR0AR	HSP74_HUMAN	Increases Expression	[80]
Nitric oxide synthase, inducible (NOS2)	OTKKIOJ1	NOS2_HUMAN	Increases Expression	[104]
Myosin-10 (MYH10)	OTXN2WXS	MYH10_HUMAN	Decreases Expression	[54]
Signal transducer and activator of transcription 3 (STAT3)	OTAAGKYZ	STAT3_HUMAN	Decreases Activity	[105]
C-C chemokine receptor type 2 (CCR2)	OTQ7T10J	CCR2_HUMAN	Decreases Expression	[106]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Decreases Expression	[39]
Signal transducer and activator of transcription 1-alpha/beta (STAT1)	OTLMBUZ6	STAT1_HUMAN	Decreases Expression	[107]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Expression	[108]
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4)	OTDK74C0	TNR4_HUMAN	Decreases Expression	[97]
ATP-binding cassette sub-family G member 1 (ABCG1)	OT5BG6MK	ABCG1_HUMAN	Decreases Expression	[50]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[109]
CX3C chemokine receptor 1 (CX3CR1)	OTIM9XT8	CX3C1_HUMAN	Decreases Expression	[110]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[111]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Expression	[87]
Nuclear receptor ROR-gamma (RORC)	OTUBFRPC	RORG_HUMAN	Decreases Expression	[42]
C-C chemokine receptor type 5 (CCR5)	OTP5FMZ4	CCR5_HUMAN	Decreases Expression	[91]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[112]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Decreases Activity	[113]
Cyclin-dependent kinase 4 inhibitor D (CDKN2D)	OT2TTZPZ	CDN2D_HUMAN	Increases Expression	[89]
Ras-related C3 botulinum toxin substrate 3 (RAC3)	OT2RE7A7	RAC3_HUMAN	Affects Localization	[41]
Transforming protein RhoA (RHOA)	OT6YOJ9N	RHOA_HUMAN	Increases Expression	[51]
Ras-related protein Rap-1A (RAP1A)	OT5RH6TI	RAP1A_HUMAN	Decreases Expression	[114]
Ras-related C3 botulinum toxin substrate 1 (RAC1)	OTKRO61U	RAC1_HUMAN	Decreases Activity	[67]
Rho GTPase-activating protein 4 (ARHGAP4)	OTXV053R	RHG04_HUMAN	Increases Expression	[51]
Cyclin-dependent kinase 5 (CDK5)	OT1YAK9F	CDK5_HUMAN	Increases Expression	[87]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Affects Localization	[80]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Phosphorylation	[115]
CD83 antigen (CD83)	OT1V4WQF	CD83_HUMAN	Decreases Expression	[39]
Myosin light chain 5 (MYL5)	OT7CQ24K	MYL5_HUMAN	Increases Expression	[61]
Caldesmon (CALD1)	OTNJKJ6Q	CALD1_HUMAN	Decreases Expression	[51]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[85]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[46]
Sterol regulatory element-binding protein 2 (SREBF2)	OTBXUNPL	SRBP2_HUMAN	Increases Expression	[116]
Forkhead box protein O1 (FOXO1)	OTPJRB6D	FOXO1_HUMAN	Decreases Localization	[113]
TNF receptor-associated factor 2 (TRAF2)	OT1MEZZN	TRAF2_HUMAN	Decreases Expression	[43]
Nuclear factor of activated T-cells, cytoplasmic 3 (NFATC3)	OTYOORME	NFAC3_HUMAN	Decreases Localization	[117]
Myosin-binding protein H (MYBPH)	OTQJBPUR	MYBPH_HUMAN	Increases Expression	[61]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[46]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)	OTXEE550	APR_HUMAN	Increases Expression	[41]
Bone morphogenetic protein receptor type-2 (BMPR2)	OTM9W547	BMPR2_HUMAN	Increases Stability	[118]
Runt-related transcription factor 2 (RUNX2)	OT97RQQM	RUNX2_HUMAN	Increases Expression	[83]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Affects Localization	[51]
Squalene monooxygenase (SQLE)	OT0GGRDO	ERG1_HUMAN	Decreases Degradation	[48]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[119]
Interferon regulatory factor 4 (IRF4)	OT1DHQ1P	IRF4_HUMAN	Decreases Expression	[120]
Tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD)	OTBOSJHO	TRADD_HUMAN	Decreases Expression	[43]
Interleukin-17A (IL17A)	OTY72FT2	IL17_HUMAN	Decreases Expression	[42]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Increases Expression	[5]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Decreases Activity	[70]
Interleukin-27 subunit alpha (IL27)	OTIS3OF8	IL27A_HUMAN	Increases Expression	[42]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[121]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Decreases Phosphorylation	[113]
Rho guanine nucleotide exchange factor 2 (ARHGEF2)	OTBQTFRT	ARHG2_HUMAN	Increases Expression	[51]
Interleukin-17F (IL17F)	OT9W9DE0	IL17F_HUMAN	Decreases Secretion	[120]
Sphingosine 1-phosphate receptor 3 (S1PR3)	OTXBIYO8	S1PR3_HUMAN	Decreases Expression	[121]
Mitogen-activated protein kinase kinase kinase 14 (MAP3K14)	OTT3DOOL	M3K14_HUMAN	Decreases Expression	[43]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Decreases Expression	[45]
Forkhead box protein P3 (FOXP3)	OTA9Z9OC	FOXP3_HUMAN	Increases Expression	[94]
Interleukin-22 (IL22)	OTW31FU9	IL22_HUMAN	Decreases Secretion	[120]
Interleukin-21 (IL21)	OTABCY4W	IL21_HUMAN	Decreases Expression	[42]
Podocin (NPHS2)	OTLCNUII	PODO_HUMAN	Increases Expression	[47]
Interleukin-23 subunit alpha (IL23A)	OTYO99HC	IL23A_HUMAN	Decreases Expression	[42]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Affects Localization	[41]
Dentin sialophosphoprotein (DSPP)	OT1TYNDN	DSPP_HUMAN	Increases Expression	[122]
7-dehydrocholesterol reductase (DHCR7)	OTLILBUI	DHCR7_HUMAN	Affects Expression	[74]
CD2-associated protein (CD2AP)	OTC76KQM	CD2AP_HUMAN	Increases Expression	[47]
Cytochrome b-245 light chain (CYBA)	OT16N9ZO	CY24A_HUMAN	Affects Response To Substance	[123]
5-hydroxytryptamine receptor 7 (HTR7)	OT44DEWB	5HT7R_HUMAN	Increases Response To Substance	[124]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10)	OT4PXBTA	TNF10_HUMAN	Increases Response To Substance	[35]
Leptin receptor (LEPR)	OT9H7G0C	LEPR_HUMAN	Affects Response To Substance	[125]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Increases ADR	[21]
Small ribosomal subunit protein mS31 (MRPS31)	OTB0OBWK	RT31_HUMAN	Decreases Response To Substance	[126]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Decreases Response To Substance	[126]
Sterol regulatory element-binding protein cleavage-activating protein (SCAP)	OTCVXOD6	SCAP_HUMAN	Affects Response To Substance	[127]
Kinesin-like protein KIF6 (KIF6)	OTDH3MR4	KIF6_HUMAN	Increases ADR	[128]
Collagen alpha-1(XIII) chain (COL13A1)	OTM9IM6J	CODA1_HUMAN	Decreases Response To Substance	[126]
5-hydroxytryptamine receptor 3B (HTR3B)	OTMGIYRE	5HT3B_HUMAN	Increases Response To Substance	[124]
ELL-associated factor 2 (EAF2)	OTSOET5L	EAF2_HUMAN	Decreases Response To Substance	[126]

Indication(s) of Rosiglitazone

Disease Entry	ICD 11	Status	REF
Chronic kidney disease	GB61	Terminated	[]

Rosiglitazone Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[136]

Rosiglitazone Interacts with 4 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[137]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[138]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[138]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Metabolism	[139]

Rosiglitazone Interacts with 589 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Increases Expression	[140]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[141]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Decreases Activity	[141]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Increases Expression	[141]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Decreases Activity	[142]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2)	OT02MSKN	3BHS2_HUMAN	Decreases Activity	[142]
Retinoic acid receptor beta (RARB)	OT367U3E	RARB_HUMAN	Increases Expression	[143]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Increases Expression	[144]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Decreases Expression	[144]
Perilipin-2 (PLIN2)	OTRXJ9UN	PLIN2_HUMAN	Increases Expression	[144]
Choriogonadotropin subunit beta 3 (CGB3)	OTVM2SU3	CGB3_HUMAN	Increases Expression	[145]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Increases Expression	[146]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Increases Expression	[146]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[146]
Golgin subfamily A member 8A (GOLGA8A)	OTSNE9EQ	GOG8A_HUMAN	Decreases Expression	[129]
CMRF35-like molecule 7 (CD300LB)	OTVC407Y	CLM7_HUMAN	Increases Expression	[129]
Signal-regulatory protein beta-1 (SIRPB1)	OTGHALWJ	SIRB1_HUMAN	Increases Expression	[129]
Regulatory factor X-associated protein (RFXAP)	OTX46DKQ	RFXAP_HUMAN	Decreases Expression	[129]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Decreases Expression	[129]
Phospholipid phosphatase 3 (PLPP3)	OTSSF7BK	PLPP3_HUMAN	Increases Expression	[129]
Low-density lipoprotein receptor class A domain-containing protein 4 (LDLRAD4)	OTQUX50Z	LRAD4_HUMAN	Increases Expression	[129]
Tumor necrosis factor ligand superfamily member 12 (TNFSF12)	OT6FQ02V	TNF12_HUMAN	Decreases Expression	[129]
F-box-like/WD repeat-containing protein TBL1X (TBL1X)	OTXQ51E0	TBL1X_HUMAN	Decreases Expression	[129]
Leukocyte immunoglobulin-like receptor subfamily A member 1 (LILRA1)	OTZ4NA7Q	LIRA1_HUMAN	Increases Expression	[129]
Short-chain dehydrogenase/reductase 3 (DHRS3)	OTSK1DTP	DHRS3_HUMAN	Increases Expression	[129]
Retinal dehydrogenase 2 (ALDH1A2)	OTJB560Z	AL1A2_HUMAN	Increases Expression	[129]
Rho-related BTB domain-containing protein 3 (RHOBTB3)	OT1BFKPH	RHBT3_HUMAN	Increases Expression	[129]
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2)	OTDLEXPN	PAPS2_HUMAN	Increases Expression	[129]
Mitogen-activated protein kinase kinase kinase 6 (MAP3K6)	OTOE0Z1R	M3K6_HUMAN	Decreases Expression	[129]
BAG family molecular chaperone regulator 2 (BAG2)	OTI6LD27	BAG2_HUMAN	Increases Expression	[129]
Adenosine deaminase (ADA)	OTOX2872	ADA_HUMAN	Increases Expression	[129]
T-cell surface glycoprotein CD1a (CD1A)	OTKSSG6N	CD1A_HUMAN	Decreases Expression	[129]
Beta-glucuronidase (GUSB)	OT9N1DK3	BGLR_HUMAN	Increases Expression	[129]
Retinol-binding protein 1 (RBP1)	OTRP1MFC	RET1_HUMAN	Increases Expression	[129]
Tumor-associated calcium signal transducer 2 (TACSTD2)	OTLSZR00	TACD2_HUMAN	Decreases Expression	[129]
Peroxisomal coenzyme A diphosphatase NUDT7 (NUDT7)	OTCPOQ6W	NUDT7_HUMAN	Decreases Expression	[129]
Interleukin-1 receptor type 1 (IL1R1)	OTTU8959	IL1R1_HUMAN	Decreases Expression	[129]
Protein C-ets-2 (ETS2)	OTPVHOZ7	ETS2_HUMAN	Increases Expression	[129]
Antigen-presenting glycoprotein CD1d (CD1D)	OT3ROU4J	CD1D_HUMAN	Increases Expression	[129]
Plasma membrane calcium-transporting ATPase 1 (ATP2B1)	OT5MXG9W	AT2B1_HUMAN	Decreases Expression	[129]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)	OT6MFOWF	TGM2_HUMAN	Increases Expression	[129]
Collagen alpha-3(V) chain (COL5A3)	OTCGC4DM	CO5A3_HUMAN	Increases Expression	[129]
Integrin alpha-E (ITGAE)	OT41KCRX	ITAE_HUMAN	Increases Expression	[129]
Rap1 GTPase-activating protein 1 (RAP1GAP)	OTC31ONQ	RPGP1_HUMAN	Decreases Expression	[129]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Increases Expression	[129]
Ribose-5-phosphate isomerase (RPIA)	OT805SMH	RPIA_HUMAN	Increases Expression	[129]
Thrombospondin-3 (THBS3)	OTDKMUBD	TSP3_HUMAN	Increases Expression	[129]
PDZ and LIM domain protein 4 (PDLIM4)	OT23LZYY	PDLI4_HUMAN	Decreases Expression	[129]
Histone H2B type 1-D (H2BC5)	OTXDTDHN	H2B1D_HUMAN	Decreases Expression	[129]
Ras-related protein Rab-15 (RAB15)	OTU0GGR3	RAB15_HUMAN	Decreases Expression	[129]
Oxidized low-density lipoprotein receptor 1 (OLR1)	OTS44RIC	OLR1_HUMAN	Increases Expression	[129]
Amyloid beta precursor like protein 2 (APLP2)	OTTFE53M	APLP2_HUMAN	Increases Expression	[129]
Myotonin-protein kinase (DMPK)	OT9XJKG4	DMPK_HUMAN	Decreases Expression	[129]
Dystrophia myotonica WD repeat-containing protein (DMWD)	OT0CBZ6F	DMWD_HUMAN	Decreases Expression	[129]
Alpha-(1,3)-fucosyltransferase 7 (FUT7)	OTJF6BSN	FUT7_HUMAN	Decreases Expression	[129]
P-selectin glycoprotein ligand 1 (SELPLG)	OTOK3301	SELPL_HUMAN	Decreases Expression	[129]
H2.0-like homeobox protein (HLX)	OT7DTH46	HLX_HUMAN	Decreases Expression	[129]
Uncharacterized protein KIAA0040 (KIAA0040)	OT27EBY3	K0040_HUMAN	Decreases Expression	[129]
Serum paraoxonase/arylesterase 2 (PON2)	OT55NCTD	PON2_HUMAN	Decreases Expression	[129]
Nicotinate-nucleotide pyrophosphorylase (QPRT)	OT6SKKLL	NADC_HUMAN	Decreases Expression	[129]
Calcitonin gene-related peptide type 1 receptor (CALCRL)	OTMGGM47	CALRL_HUMAN	Decreases Expression	[129]
Zinc finger protein SNAI3 (SNAI3)	OTG9DI66	SNAI3_HUMAN	Increases Expression	[129]
Pleckstrin homology-like domain family A member 2 (PHLDA2)	OTMV9DPP	PHLA2_HUMAN	Decreases Expression	[129]
Late cornified envelope-like proline-rich protein 1 (LELP1)	OTOQIVV0	LELP1_HUMAN	Decreases Expression	[129]
Protein sel-1 homolog 3 (SEL1L3)	OT10N6Z2	SE1L3_HUMAN	Increases Expression	[129]
Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1)	OTXIGC6I	LAIR1_HUMAN	Increases Expression	[129]
Myogenesis-regulating glycosidase (MYORG)	OTVK4VMH	MYORG_HUMAN	Decreases Expression	[129]
Uncharacterized protein C16orf46 (C16ORF46)	OT8FDG3A	CP046_HUMAN	Decreases Expression	[129]
Phospholipase B-like 1 (PLBD1)	OTHYEB4W	PLBL1_HUMAN	Increases Expression	[129]
Low-density lipoprotein receptor-related protein 11 (LRP11)	OTQNI7L8	LRP11_HUMAN	Decreases Expression	[129]
Sodium-independent sulfate anion transporter (SLC26A11)	OTWBV9CR	S2611_HUMAN	Increases Expression	[129]
Cerebellar degeneration-related protein 2-like (CDR2L)	OT5UVB1J	CDR2L_HUMAN	Decreases Expression	[129]
SLIT and NTRK-like protein 4 (SLITRK4)	OTSCN5AM	SLIK4_HUMAN	Increases Expression	[129]
Retinol dehydrogenase 10 (RDH10)	OTL9FSGF	RDH10_HUMAN	Increases Expression	[129]
Glycerol-3-phosphate dehydrogenase 1-like protein (GPD1L)	OTVLWW9T	GPD1L_HUMAN	Decreases Expression	[129]
Sesquipedalian-1 (PHETA1)	OT4IMC0X	SESQ1_HUMAN	Decreases Expression	[129]
Refilin-B (RFLNB)	OTI7ZM75	RFLB_HUMAN	Increases Expression	[129]
Uncharacterized protein FAM241A (FAM241A)	OTC12ETA	F241A_HUMAN	Decreases Expression	[129]
F-box only protein 15 (FBXO15)	OTJHEFE5	FBX15_HUMAN	Increases Expression	[129]
RalBP1-associated Eps domain-containing protein 2 (REPS2)	OTSE3TRP	REPS2_HUMAN	Decreases Expression	[129]
CMRF35-like molecule 1 (CD300LF)	OTQWJGSR	CLM1_HUMAN	Increases Expression	[129]
Serine-rich single-pass membrane protein 1 (SSMEM1)	OTH78CH0	SSMM1_HUMAN	Decreases Expression	[129]
Interactor protein for cytohesin exchange factors 1 (IPCEF1)	OTOUIHID	ICEF1_HUMAN	Decreases Expression	[129]
Cortactin-binding protein 2 (CTTNBP2)	OT4CL1EW	CTTB2_HUMAN	Decreases Expression	[129]
Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)	OT6FQ1K3	M4K1_HUMAN	Decreases Expression	[129]
Kinesin-like protein KIFC2 (KIFC2)	OTLTVM7V	KIFC2_HUMAN	Decreases Expression	[129]
Metalloendopeptidase OMA1, mitochondrial (OMA1)	OT0JRVY7	OMA1_HUMAN	Increases Expression	[129]
PDZ and LIM domain protein 2 (PDLIM2)	OTEURRPD	PDLI2_HUMAN	Decreases Expression	[129]
Fatty acyl-CoA reductase 2 (FAR2)	OTRYY709	FACR2_HUMAN	Increases Expression	[129]
PML-RARA-regulated adapter molecule 1 (PRAM1)	OTZN3DWD	PRAM_HUMAN	Increases Expression	[129]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[129]
Dehydrogenase/reductase SDR family member 9 (DHRS9)	OTB1WOZA	DHRS9_HUMAN	Increases Expression	[129]
Caspase recruitment domain-containing protein 14 (CARD14)	OTADQHOV	CAR14_HUMAN	Increases Expression	[129]
TBC1 domain family member 2A (TBC1D2)	OTSGHPD0	TBD2A_HUMAN	Increases Expression	[129]
N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 (B3GNT4)	OTRKV2N8	B3GN4_HUMAN	Increases Expression	[129]
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1)	OT4U7SBG	GBRL1_HUMAN	Increases Expression	[129]
Dendritic cell-specific transmembrane protein (DCSTAMP)	OTFKRP2H	DCSTP_HUMAN	Increases Expression	[129]
Homeodomain-interacting protein kinase 2 (HIPK2)	OTDB7QC3	HIPK2_HUMAN	Increases Expression	[129]
Ribokinase (RBKS)	OTDG01Y9	RBSK_HUMAN	Increases Expression	[129]
Tensin-1 (TNS1)	OTZ8S1PL	TENS1_HUMAN	Decreases Expression	[129]
Echinoderm microtubule-associated protein-like 4 (EML4)	OTJC45TA	EMAL4_HUMAN	Increases Expression	[129]
Interleukin-1 receptor accessory protein (IL1RAP)	OTEU321R	IL1AP_HUMAN	Decreases Expression	[129]
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC (MAN1C1)	OT44TM7D	MA1C1_HUMAN	Decreases Expression	[129]
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (AGPAT4)	OT5CTQKO	PLCD_HUMAN	Increases Expression	[129]
Ras-related protein Rab-20 (RAB20)	OTP9OOVS	RAB20_HUMAN	Increases Expression	[129]
ETS homologous factor (EHF)	OTY6TPWD	EHF_HUMAN	Increases Expression	[129]
Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C (MGAT4C)	OTQ2R629	MGT4C_HUMAN	Decreases Expression	[129]
DnaJ homolog subfamily C member 5B (DNAJC5B)	OTHDMM7O	DNJ5B_HUMAN	Increases Expression	[129]
CMRF35-like molecule 8 (CD300A)	OTGBQE0Z	CLM8_HUMAN	Increases Expression	[129]
Meteorin (METRN)	OTI2645G	METRN_HUMAN	Decreases Expression	[129]
Adherens junction-associated protein 1 (AJAP1)	OTAAW121	AJAP1_HUMAN	Increases Expression	[129]
Paladin (PALD1)	OTLGUM8H	PALD_HUMAN	Decreases Expression	[129]
Protein NDRG2 (NDRG2)	OT5L6KD7	NDRG2_HUMAN	Decreases Expression	[129]
Phosphatidylinositide phosphatase SAC2 (INPP5F)	OTPKUY50	SAC2_HUMAN	Increases Expression	[129]
Transducin beta-like protein 2 (TBL2)	OTCIMSK8	TBL2_HUMAN	Increases Expression	[129]
Transmembrane protein 14A (TMEM14A)	OTANQA6G	TM14A_HUMAN	Decreases Expression	[129]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Increases Expression	[147]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Decreases Expression	[147]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)	OTA675TJ	GTR1_HUMAN	Decreases Expression	[147]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Decreases Expression	[147]
Lipid transferase CIDEC (CIDEC)	OTMDZ56K	CIDEC_HUMAN	Increases Expression	[147]
Resistin (RETN)	OTW5Z1NH	RETN_HUMAN	Decreases Expression	[147]
Proline dehydrogenase 1, mitochondrial (PRODH)	OT7SQ1C7	PROD_HUMAN	Increases Expression	[148]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Expression	[149]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Expression	[150]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[150]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[34]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Decreases Activity	[151]
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Decreases Activity	[151]
Cytochrome P450 2J2 (CYP2J2)	OTJBTEH8	CP2J2_HUMAN	Increases Expression	[152]
Cytochrome c oxidase subunit 1 (COX1)	OTG3O9BN	COX1_HUMAN	Increases Expression	[153]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[153]
Succinate dehydrogenase flavoprotein subunit, mitochondrial (SDHA)	OTOJ8QFF	SDHA_HUMAN	Increases Expression	[153]
Transcription factor A, mitochondrial (TFAM)	OTXXV5V7	TFAM_HUMAN	Increases Expression	[153]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Expression	[153]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[154]
Fucose mutarotase (FUOM)	OTM201HH	FUCM_HUMAN	Decreases Expression	[130]
Myotubularin-related protein 11 (MTMR11)	OTHL2O08	MTMRB_HUMAN	Decreases Expression	[130]
Aspartate dehydrogenase domain-containing protein (ASPDH)	OTN38YBY	ASPDH_HUMAN	Decreases Expression	[130]
D-dopachrome decarboxylase-like protein (DDTL)	OTG1LU87	DDTL_HUMAN	Decreases Expression	[130]
Espin (ESPN)	OT7Z6LX2	ESPN_HUMAN	Decreases Expression	[130]
Mannan-binding lectin serine protease 2 (MASP2)	OTBFTUZ1	MASP2_HUMAN	Decreases Expression	[130]
Sodium/nucleoside cotransporter 1 (SLC28A1)	OTXWVV9O	S28A1_HUMAN	Decreases Expression	[130]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Decreases Expression	[130]
Phospholipid phosphatase 1 (PLPP1)	OT0IIMI5	PLPP1_HUMAN	Increases Expression	[130]
Kynurenine 3-monooxygenase (KMO)	OT3MRMM9	KMO_HUMAN	Decreases Expression	[130]
Solute carrier family 22 member 1 (SLC22A1)	OT7817I4	S22A1_HUMAN	Decreases Expression	[130]
Calpain-5 (CAPN5)	OTQ8QM7K	CAN5_HUMAN	Decreases Expression	[130]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Decreases Expression	[130]
Protein MTSS 1 (MTSS1)	OT5DTDO2	MTSS1_HUMAN	Decreases Expression	[130]
Synaptotagmin-7 (SYT7)	OTBWAOWY	SYT7_HUMAN	Decreases Expression	[130]
Glucose-6-phosphate exchanger SLC37A4 (SLC37A4)	OTLCYA32	G6PT1_HUMAN	Decreases Expression	[130]
Perilipin-1 (PLIN1)	OT3OAAZ4	PLIN1_HUMAN	Increases Expression	[130]
Peroxisomal membrane protein 11A (PEX11A)	OT8MJ9CJ	PX11A_HUMAN	Increases Expression	[130]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21)	OT3EDGXO	TNR21_HUMAN	Increases Expression	[130]
Lathosterol oxidase (SC5D)	OT41KMW4	SC5D_HUMAN	Decreases Expression	[130]
Organic cation/carnitine transporter 2 (SLC22A5)	OTC36TYB	S22A5_HUMAN	Increases Expression	[130]
ABC-type organic anion transporter ABCA8 (ABCA8)	OTCWLX6N	ABCA8_HUMAN	Decreases Expression	[130]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Decreases Expression	[130]
Ornithine transcarbamylase, mitochondrial (OTC)	OTJ57GGA	OTC_HUMAN	Decreases Expression	[130]
Coagulation factor X (F10)	OT2BLK17	FA10_HUMAN	Decreases Expression	[130]
Coagulation factor XII (F12)	OTBFD2FU	FA12_HUMAN	Decreases Expression	[130]
Complement factor B (CFB)	OTZITNEJ	CFAB_HUMAN	Decreases Expression	[130]
Serine protease inhibitor Kazal-type 1 (SPINK1)	OTSUVAL2	ISK1_HUMAN	Increases Expression	[130]
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)	OT7KZMP2	DRA_HUMAN	Decreases Expression	[130]
Plasma kallikrein (KLKB1)	OTGSEISX	KLKB1_HUMAN	Decreases Expression	[130]
Vitamin K-dependent protein C (PROC)	OTGVH484	PROC_HUMAN	Decreases Expression	[130]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Expression	[130]
Glycophorin-C (GYPC)	OTOEDR7O	GLPC_HUMAN	Increases Expression	[130]
Fructose-bisphosphate aldolase B (ALDOB)	OT7FR69A	ALDOB_HUMAN	Decreases Expression	[130]
Arginase-1 (ARG1)	OTHZITAM	ARGI1_HUMAN	Decreases Expression	[130]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Expression	[130]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Decreases Expression	[130]
Serine protease hepsin (HPN)	OT7QNA61	HEPS_HUMAN	Decreases Expression	[130]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Decreases Expression	[130]
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Decreases Expression	[130]
Apolipoprotein A-IV (APOA4)	OT466POQ	APOA4_HUMAN	Decreases Expression	[130]
Asialoglycoprotein receptor 2 (ASGR2)	OTFSGOVY	ASGR2_HUMAN	Decreases Expression	[130]
Complement component C8 alpha chain (C8A)	OTIJ65J4	CO8A_HUMAN	Decreases Expression	[130]
Complement component C8 beta chain (C8B)	OTGDJJOK	CO8B_HUMAN	Decreases Expression	[130]
Complement component C8 gamma chain (C8G)	OTZM027I	CO8G_HUMAN	Decreases Expression	[130]
All-trans-retinol dehydrogenase ADH4 (ADH4)	OTKDKKNG	ADH4_HUMAN	Decreases Expression	[130]
Complement factor H (CFH)	OTAGKQTJ	CFAH_HUMAN	Decreases Expression	[130]
Coagulation factor VII (F7)	OTGNJ97M	FA7_HUMAN	Decreases Expression	[130]
Mannose-binding protein C (MBL2)	OTS63HG5	MBL2_HUMAN	Increases Expression	[130]
Cytochrome P450 2A6 (CYP2A6)	OT52TWG3	CP2A6_HUMAN	Decreases Expression	[130]
Nucleoprotein TPR (TPR)	OTUBBA4W	TPR_HUMAN	Decreases Expression	[130]
5-aminolevulinate synthase, non-specific, mitochondrial (ALAS1)	OTQY6ZSF	HEM1_HUMAN	Increases Expression	[130]
D-amino-acid oxidase (DAO)	OTZFVRIN	OXDA_HUMAN	Decreases Expression	[130]
Carboxypeptidase N catalytic chain (CPN1)	OTKXIFI6	CBPN_HUMAN	Decreases Expression	[130]
Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1)	OT7US3NO	SIAT1_HUMAN	Decreases Expression	[130]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFKFB1)	OTTHX4NB	F261_HUMAN	Decreases Expression	[130]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Expression	[130]
Insulin-like growth factor-binding protein 2 (IGFBP2)	OTG1P60E	IBP2_HUMAN	Decreases Expression	[130]
Cytochrome P450 2A7 (CYP2A7)	OTRJ3P2Z	CP2A7_HUMAN	Decreases Expression	[130]
5'-nucleotidase (NT5E)	OT7J5LT6	5NTD_HUMAN	Decreases Expression	[130]
Sterol carrier protein 2 (SCP2)	OTPAFCPQ	SCP2_HUMAN	Decreases Expression	[130]
Fibroblast growth factor receptor 3 (FGFR3)	OTSAXDIL	FGFR3_HUMAN	Decreases Expression	[130]
Cytochrome P450 7A1 (CYP7A1)	OT8Z5KLD	CP7A1_HUMAN	Decreases Expression	[130]
Arylacetamide deacetylase (AADAC)	OT8VACT2	AAAD_HUMAN	Increases Expression	[130]
Vitamin K-dependent protein Z (PROZ)	OTI3TXBE	PROZ_HUMAN	Decreases Expression	[130]
Receptor-type tyrosine-protein phosphatase epsilon (PTPRE)	OTOD5NID	PTPRE_HUMAN	Increases Expression	[130]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4)	OTMWFDAC	AT2B4_HUMAN	Increases Expression	[130]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Decreases Expression	[130]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Decreases Expression	[130]
G0/G1 switch protein 2 (G0S2)	OT8FL49L	G0S2_HUMAN	Decreases Expression	[130]
Alcohol dehydrogenase 6 (ADH6)	OTS7DYH9	ADH6_HUMAN	Decreases Expression	[130]
Proprotein convertase subtilisin/kexin type 6 (PCSK6)	OTI64BU4	PCSK6_HUMAN	Decreases Expression	[130]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Decreases Expression	[130]
Kallistatin (SERPINA4)	OTBK0GG7	KAIN_HUMAN	Decreases Expression	[130]
D-dopachrome decarboxylase (DDT)	OTF5HTYL	DOPD_HUMAN	Decreases Expression	[130]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)	OTEOT8GI	GFRP_HUMAN	Decreases Expression	[130]
Pyruvate kinase PKLR (PKLR)	OTTTM1QI	KPYR_HUMAN	Decreases Expression	[130]
Carbamoyl-phosphate synthase , mitochondrial (CPS1)	OTXV8NSR	CPSM_HUMAN	Decreases Expression	[130]
Cystathionine gamma-lyase (CTH)	OTC90LA0	CGL_HUMAN	Decreases Expression	[130]
CD70 antigen (CD70)	OTHB2AL1	CD70_HUMAN	Increases Expression	[130]
Cytochrome P450 2C18 (CYP2C18)	OTY687L9	CP2CI_HUMAN	Decreases Expression	[130]
Carbonic anhydrase 5A, mitochondrial (CA5A)	OTP9M7VW	CAH5A_HUMAN	Decreases Expression	[130]
Nuclear receptor ROR-alpha (RORA)	OTGQT12P	RORA_HUMAN	Decreases Expression	[130]
Cystathionine beta-synthase (CBS)	OT46FSKD	CBS_HUMAN	Decreases Expression	[130]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	OTJ6FM9F	G6PC1_HUMAN	Decreases Expression	[130]
Pigment epithelium-derived factor (SERPINF1)	OTWZH98J	PEDF_HUMAN	Decreases Expression	[130]
Isoleucine--tRNA ligase, cytoplasmic (IARS1)	OT9WXH5N	SYIC_HUMAN	Increases Expression	[130]
Afamin (AFM)	OTPOR8IO	AFAM_HUMAN	Decreases Expression	[130]
5-hydroxytryptamine receptor 3A (HTR3A)	OTAIV1AK	5HT3A_HUMAN	Increases Expression	[130]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Increases Expression	[130]
Flavin-containing monooxygenase 5 (FMO5)	OTTILF8T	FMO5_HUMAN	Decreases Expression	[130]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Increases Expression	[130]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)	OT714BUO	AL3A2_HUMAN	Increases Expression	[130]
Stanniocalcin-1 (STC1)	OTGVVXYF	STC1_HUMAN	Decreases Expression	[130]
Trifunctional enzyme subunit beta, mitochondrial (HADHB)	OT4Y1I62	ECHB_HUMAN	Increases Expression	[130]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Decreases Expression	[130]
Large ribosomal subunit protein eL15 (RPL15)	OT7Y42LL	RL15_HUMAN	Increases Expression	[130]
Protein BTG1 (BTG1)	OTVJ2CDM	BTG1_HUMAN	Decreases Expression	[130]
Estrogen-related receptor gamma (ESRRG)	OTC3A0KU	ERR3_HUMAN	Decreases Expression	[130]
Cytochrome P450 4F2 (CYP4F2)	OTKILAER	CP4F2_HUMAN	Decreases Expression	[130]
T-complex protein 1 subunit beta (CCT2)	OTW1VV4E	TCPB_HUMAN	Increases Expression	[130]
Sushi repeat-containing protein SRPX (SRPX)	OT5B9LXS	SRPX_HUMAN	Increases Expression	[130]
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Decreases Expression	[130]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2)	OTQR5SXD	CX6A2_HUMAN	Decreases Expression	[130]
Aminoacylase-1 (ACY1)	OT9WU7X3	ACY1_HUMAN	Decreases Expression	[130]
Transcription factor SOX-4 (SOX4)	OTSS40SS	SOX4_HUMAN	Increases Expression	[130]
Follistatin-related protein 1 (FSTL1)	OT6KEZUD	FSTL1_HUMAN	Increases Expression	[130]
Secreted phosphoprotein 24 (SPP2)	OTX254AR	SPP24_HUMAN	Decreases Expression	[130]
Syntaxin-3 (STX3)	OT4CIWLJ	STX3_HUMAN	Increases Expression	[130]
Protein phosphatase 1 regulatory subunit 1A (PPP1R1A)	OTGTAGCV	PPR1A_HUMAN	Decreases Expression	[130]
Dihydropyrimidinase (DPYS)	OTLTUIVL	DPYS_HUMAN	Decreases Expression	[130]
SPARC-like protein 1 (SPARCL1)	OT74DWMV	SPRL1_HUMAN	Decreases Expression	[130]
Laminin subunit alpha-4 (LAMA4)	OTHI7TA0	LAMA4_HUMAN	Increases Expression	[130]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Increases Expression	[130]
Hydroxyacylglutathione hydrolase, mitochondrial (HAGH)	OTYMDAYV	GLO2_HUMAN	Decreases Expression	[130]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2)	OTJ8LX4N	PCKGM_HUMAN	Decreases Expression	[130]
BTB/POZ domain-containing protein 16 (BTBD16)	OT04G9HG	BTBDG_HUMAN	Decreases Expression	[130]
Triokinase/FMN cyclase (TKFC)	OTTWXIOI	TKFC_HUMAN	Decreases Expression	[130]
Ectonucleoside triphosphate diphosphohydrolase 8 (ENTPD8)	OTB9GJ1V	ENTP8_HUMAN	Decreases Expression	[130]
Kidney mitochondrial carrier protein 1 (SLC25A30)	OT2VA5PI	KMCP1_HUMAN	Increases Expression	[130]
Early estrogen-induced gene 1 protein (EEIG1)	OT2BMEAE	EEIG1_HUMAN	Increases Expression	[130]
Solute carrier family 22 member 10 (SLC22A10)	OTUVJI3H	S22AA_HUMAN	Decreases Expression	[130]
Acyl-coenzyme A synthetase ACSM5, mitochondrial (ACSM5)	OTWMDQPX	ACSM5_HUMAN	Decreases Expression	[130]
Iodotyrosine deiodinase 1 (IYD)	OT8BQWTE	IYD1_HUMAN	Decreases Expression	[130]
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 4 (LINGO4)	OTLADERJ	LIGO4_HUMAN	Decreases Expression	[130]
Alkylglycerol monooxygenase (AGMO)	OTGMAHAT	ALKMO_HUMAN	Decreases Expression	[130]
Ras and Rab interactor-like protein (RINL)	OTZ0NDKE	RINL_HUMAN	Increases Expression	[130]
Hemojuvelin (HJV)	OT4235J2	RGMC_HUMAN	Decreases Expression	[130]
Mitochondrial S-adenosylmethionine carrier protein (SLC25A26)	OTSF2NXD	SAMC_HUMAN	Increases Expression	[130]
Equilibrative nucleoside transporter 4 (SLC29A4)	OTWTZXMX	S29A4_HUMAN	Increases Expression	[130]
Transient receptor potential cation channel subfamily M member 8 (TRPM8)	OT7ACGYK	TRPM8_HUMAN	Increases Expression	[130]
L-xylulose reductase (DCXR)	OTYVXRXB	DCXR_HUMAN	Decreases Expression	[130]
Organic solute transporter subunit alpha (SLC51A)	OTDJRZ0P	OSTA_HUMAN	Decreases Expression	[130]
Organic solute transporter subunit beta (SLC51B)	OT4WYPSR	OSTB_HUMAN	Increases Expression	[130]
2-acylglycerol O-acyltransferase 3 (MOGAT3)	OTPGLUBS	MOGT3_HUMAN	Decreases Expression	[130]
Src kinase-associated phosphoprotein 1 (SKAP1)	OTD4ZKAL	SKAP1_HUMAN	Decreases Expression	[130]
Cell division cycle protein 20 homolog B (CDC20B)	OTO5F8CF	CD20B_HUMAN	Decreases Expression	[130]
Transmembrane protease serine 6 (TMPRSS6)	OTA17R1M	TMPS6_HUMAN	Decreases Expression	[130]
Organic anion transporter 7 (SLC22A9)	OTO4BJCC	S22A9_HUMAN	Decreases Expression	[130]
Volume-regulated anion channel subunit LRRC8A (LRRC8A)	OT23OE7H	LRC8A_HUMAN	Decreases Expression	[130]
Tumor protein p53-inducible nuclear protein 2 (TP53INP2)	OT0GTBXO	T53I2_HUMAN	Decreases Expression	[130]
Probable inactive peptidyl-prolyl cis-trans isomerase-like 6 (PPIL6)	OTOZQMQE	PPIL6_HUMAN	Increases Expression	[130]
NADH dehydrogenase 1 alpha subcomplex assembly factor 2 (NDUFAF2)	OTC8QPRS	NDUF2_HUMAN	Increases Expression	[130]
Lysoplasmalogenase TMEM86B (TMEM86B)	OTOKL8BF	TM86B_HUMAN	Decreases Expression	[130]
Interleukin-22 receptor subunit alpha-1 (IL22RA1)	OTGVKLBR	I22R1_HUMAN	Decreases Expression	[130]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A)	OTVG1VG0	NLS1_HUMAN	Decreases Expression	[130]
Mixed lineage kinase domain-like protein (MLKL)	OTDSLC81	MLKL_HUMAN	Increases Expression	[130]
Clarin-3 (CLRN3)	OTZDNL65	CLRN3_HUMAN	Decreases Expression	[130]
Phosphatidylinositol 4-kinase type 2-beta (PI4K2B)	OT0D51QP	P4K2B_HUMAN	Decreases Expression	[130]
Serine/threonine-protein kinase BRSK1 (BRSK1)	OT6N35Q0	BRSK1_HUMAN	Decreases Expression	[130]
Transmembrane protein 171 (TMEM171)	OTJPHOWW	TM171_HUMAN	Increases Expression	[130]
Thyroid hormone-inducible hepatic protein (THRSP)	OTKYE01L	THRSP_HUMAN	Decreases Expression	[130]
Retinol dehydrogenase 5 (RDH5)	OTYBZHCC	RDH5_HUMAN	Decreases Expression	[130]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Increases Expression	[130]
Proteoglycan 4 (PRG4)	OT34NR3N	PRG4_HUMAN	Decreases Expression	[130]
Solute carrier organic anion transporter family member 2A1 (SLCO2A1)	OT3062CA	SO2A1_HUMAN	Increases Expression	[130]
Liver-expressed antimicrobial peptide 2 (LEAP2)	OTUOPIS5	LEAP2_HUMAN	Decreases Expression	[130]
Interferon-stimulated gene 20 kDa protein (ISG20)	OTCWRJJW	ISG20_HUMAN	Decreases Expression	[130]
GTP-binding protein Rhes (RASD2)	OTETA815	RHES_HUMAN	Increases Expression	[130]
FXYD domain-containing ion transport regulator 5 (FXYD5)	OT81DIOD	FXYD5_HUMAN	Increases Expression	[130]
Endoplasmic reticulum resident protein 27 (ERP27)	OTVMGE2H	ERP27_HUMAN	Decreases Expression	[130]
E3 ubiquitin-protein ligase RNF125 (RNF125)	OTBD1Q3X	RN125_HUMAN	Decreases Expression	[130]
Uncharacterized protein C11orf24 (C11ORF24)	OT2DOJ6E	CK024_HUMAN	Decreases Expression	[130]
Calmodulin-like protein 4 (CALML4)	OT6DD5EW	CALL4_HUMAN	Decreases Expression	[130]
Transmembrane protein 41A (TMEM41A)	OTAAULKY	TM41A_HUMAN	Decreases Expression	[130]
SH2 domain-containing adapter protein D (SHD)	OTGTHL5V	SHD_HUMAN	Decreases Expression	[130]
Membrane-spanning 4-domains subfamily A member 10 (MS4A10)	OTH3LAUX	M4A10_HUMAN	Decreases Expression	[130]
Serine protease FAM111A (FAM111A)	OTVLARLG	F111A_HUMAN	Decreases Expression	[130]
Tribbles homolog 3 (TRIB3)	OTG5OS7X	TRIB3_HUMAN	Decreases Expression	[130]
Serine incorporator 2 (SERINC2)	OTZ039U0	SERC2_HUMAN	Increases Expression	[130]
G-protein coupled estrogen receptor 1 (GPER1)	OTUK0TDC	GPER1_HUMAN	Decreases Expression	[130]
Sodium-coupled neutral amino acid transporter 3 (SLC38A3)	OTCHH25G	S38A3_HUMAN	Decreases Expression	[130]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1)	OTU230MC	ISCA1_HUMAN	Increases Expression	[130]
Guanine nucleotide-binding protein-like 3 (GNL3)	OTILGYO4	GNL3_HUMAN	Increases Expression	[130]
Group XIIB secretory phospholipase A2-like protein (PLA2G12B)	OTY7GXA6	PG12B_HUMAN	Decreases Expression	[130]
Angiopoietin-related protein 4 (ANGPTL4)	OTQL5SPX	ANGL4_HUMAN	Increases Expression	[130]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Increases Expression	[130]
Alanine--glyoxylate aminotransferase 2, mitochondrial (AGXT2)	OTO6QUTM	AGT2_HUMAN	Decreases Expression	[130]
Transmembrane 6 superfamily member 2 (TM6SF2)	OTXMU5ZV	TM6S2_HUMAN	Decreases Expression	[130]
DNA-directed RNA polymerase I subunit RPA49 (POLR1E)	OTCBMKW6	RPA49_HUMAN	Increases Expression	[130]
Cytosolic beta-glucosidase (GBA3)	OT86XWU2	GBA3_HUMAN	Decreases Expression	[130]
2-aminomuconic semialdehyde dehydrogenase (ALDH8A1)	OTINY3MW	AL8A1_HUMAN	Decreases Expression	[130]
Mid1-interacting protein 1 (MID1IP1)	OTFCORJM	M1IP1_HUMAN	Decreases Expression	[130]
NADPH oxidase 4 (NOX4)	OTTYQ097	NOX4_HUMAN	Decreases Expression	[130]
PI-PLC X domain-containing protein 1 (PLCXD1)	OTU7KCQL	PLCX1_HUMAN	Decreases Expression	[130]
Ethanolamine kinase 2 (ETNK2)	OT5S1Z75	EKI2_HUMAN	Decreases Expression	[130]
Spermatogenesis- and oogenesis-specific basic helix-loop-helix-containing protein 2 (SOHLH2)	OTB9EM6C	SOLH2_HUMAN	Increases Expression	[130]
H/ACA ribonucleoprotein complex subunit 1 (GAR1)	OTA580RX	GAR1_HUMAN	Increases Expression	[130]
Cingulin (CGN)	OTBCQ8AQ	CING_HUMAN	Decreases Expression	[130]
Alpha-aminoadipic semialdehyde synthase, mitochondrial (AASS)	OTYCN07T	AASS_HUMAN	Decreases Expression	[130]
Lipid transferase CIDEB (CIDEB)	OT873IYM	CIDEB_HUMAN	Decreases Expression	[130]
Annexin A10 (ANXA10)	OTA8LWSL	ANX10_HUMAN	Decreases Expression	[130]
Transcription factor SOX-13 (SOX13)	OTCIF6KC	SOX13_HUMAN	Decreases Expression	[130]
Microtubule-associated protein RP/EB family member 3 (MAPRE3)	OTSCLETV	MARE3_HUMAN	Increases Expression	[130]
Regulating synaptic membrane exocytosis protein 2 (RIMS2)	OTQASWDH	RIMS2_HUMAN	Decreases Expression	[130]
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C)	OTEU05TX	PPR3C_HUMAN	Decreases Expression	[130]
Endothelial lipase (LIPG)	OTHEE942	LIPG_HUMAN	Decreases Expression	[130]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Increases Expression	[130]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Decreases Expression	[130]
Agouti-related protein (AGRP)	OT7XRHWU	AGRP_HUMAN	Increases Expression	[131]
Golgi integral membrane protein 4 (GOLIM4)	OTB5NV8A	GOLI4_HUMAN	Decreases Expression	[131]
Long-chain fatty acid transport protein 2 (SLC27A2)	OT7JEG5F	S27A2_HUMAN	Decreases Expression	[131]
Rho guanine nucleotide exchange factor 10 (ARHGEF10)	OTHJ1Y4I	ARHGA_HUMAN	Decreases Expression	[131]
Secretory carrier-associated membrane protein 1 (SCAMP1)	OTFS4IKJ	SCAM1_HUMAN	Increases Expression	[131]
Protein phosphatase 1D (PPM1D)	OT8NLZ9D	PPM1D_HUMAN	Increases Expression	[131]
Cochlin (COCH)	OTBEHD89	COCH_HUMAN	Decreases Expression	[131]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20)	OT6CLFXB	MCAT_HUMAN	Decreases Expression	[131]
NUAK family SNF1-like kinase 1 (NUAK1)	OTLLHJJQ	NUAK1_HUMAN	Decreases Expression	[131]
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IB (MAN1A2)	OTITCN3Q	MA1A2_HUMAN	Decreases Expression	[131]
E3 ubiquitin-protein ligase listerin (LTN1)	OTIW2HTX	LTN1_HUMAN	Decreases Expression	[131]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1)	OTERJ4VQ	SO2B1_HUMAN	Decreases Expression	[131]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[131]
Tyrosine-protein kinase Fgr (FGR)	OTCUYU9F	FGR_HUMAN	Increases Expression	[131]
RNA-binding protein RO60 (RO60)	OTLGM5A8	RO60_HUMAN	Decreases Expression	[131]
Fos-related antigen 1 (FOSL1)	OT9YTYMB	FOSL1_HUMAN	Increases Expression	[131]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[131]
Retinoic acid receptor RXR-alpha (RXRA)	OTP1TBDM	RXRA_HUMAN	Decreases Expression	[131]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[131]
ETS domain-containing protein Elk-4 (ELK4)	OTVSSEOE	ELK4_HUMAN	Increases Expression	[131]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[131]
Serine/threonine-protein kinase SIK1 (SIK1)	OT6FCHME	SIK1_HUMAN	Increases Expression	[131]
Cyclin-dependent kinase 6 (CDK6)	OTR95N0X	CDK6_HUMAN	Decreases Expression	[131]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[131]
Adenylate cyclase type 1 (ADCY1)	OTSLLFZO	ADCY1_HUMAN	Decreases Expression	[131]
Zinc finger protein Rlf (RLF)	OTCSPZVK	RLF_HUMAN	Increases Expression	[131]
Kelch-like ECH-associated protein 1 (KEAP1)	OTFHOD0C	KEAP1_HUMAN	Increases Expression	[131]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Decreases Expression	[131]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Decreases Expression	[131]
Protein disulfide-isomerase A5 (PDIA5)	OT76ZSX5	PDIA5_HUMAN	Decreases Expression	[131]
Neuronal regeneration-related protein (NREP)	OT2AZPKK	NREP_HUMAN	Decreases Expression	[131]
Dual specificity protein phosphatase 5 (DUSP5)	OTH96RA7	DUS5_HUMAN	Increases Expression	[131]
Atos homolog protein A (ATOSA)	OTWFM5G0	ATOSA_HUMAN	Decreases Expression	[131]
Glycerol-3-phosphate acyltransferase 3 (GPAT3)	OTJUGPK0	GPAT3_HUMAN	Increases Expression	[131]
Ribosomal protein eS27-like (RPS27L)	OTZWHU0N	RS27L_HUMAN	Decreases Expression	[131]
Protein mono-ADP-ribosyltransferase TIPARP (TIPARP)	OTZ4BG4B	PARPT_HUMAN	Increases Expression	[131]
Extracellular sulfatase Sulf-2 (SULF2)	OTIXMUVL	SULF2_HUMAN	Decreases Expression	[131]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1)	OT0HYZIU	S3TC1_HUMAN	Increases Expression	[131]
Uncharacterized protein C4orf3 (C4ORF3)	OT6TFN1O	CD003_HUMAN	Decreases Expression	[131]
Sortilin-related receptor (SORL1)	OTQ8FFNS	SORL_HUMAN	Decreases Expression	[131]
GTP-binding protein Rit1 (RIT1)	OTVNOGOH	RIT1_HUMAN	Increases Expression	[131]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1)	OT2363Z9	T53I1_HUMAN	Decreases Expression	[131]
Protein orai-3 (ORAI3)	OTUP3OH3	ORAI3_HUMAN	Decreases Expression	[131]
Ectonucleoside triphosphate diphosphohydrolase 7 (ENTPD7)	OT3QER33	ENTP7_HUMAN	Decreases Expression	[131]
Oxidative stress-induced growth inhibitor 1 (OSGIN1)	OT9KIVZW	OSGI1_HUMAN	Increases Expression	[131]
Insulin-induced gene 2 protein (INSIG2)	OTX4VY51	INSI2_HUMAN	Decreases Expression	[131]
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2)	OTM3CQZT	BIG2_HUMAN	Increases Expression	[131]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Affects Localization	[155]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[155]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Increases Expression	[155]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Increases Expression	[156]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Decreases Expression	[157]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[158]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Decreases Expression	[157]
Centrin-3 (CETN3)	OTG4PL7H	CETN3_HUMAN	Decreases Expression	[157]
Protein phosphatase 1G (PPM1G)	OTLZL9CG	PPM1G_HUMAN	Increases Expression	[157]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[135]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Increases Expression	[45]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[135]
Death effector domain-containing protein (DEDD)	OTIL349E	DEDD_HUMAN	Increases Expression	[157]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[157]
STAM-binding protein (STAMBP)	OTOT2OXM	STABP_HUMAN	Decreases Expression	[157]
Centrosomal protein 43 (CEP43)	OT8TRHCF	CEP43_HUMAN	Decreases Expression	[157]
Cytochrome b5 (CYB5A)	OT6SN4RM	CYB5_HUMAN	Affects Expression	[132]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Increases Expression	[159]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Phosphorylation	[160]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Affects Expression	[132]
Carbonic anhydrase 1 (CA1)	OTNFBVVQ	CAH1_HUMAN	Affects Expression	[132]
Carbonic anhydrase 2 (CA2)	OTJRMUAG	CAH2_HUMAN	Affects Expression	[132]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[161]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Decreases Expression	[162]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Expression	[163]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Increases Expression	[164]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Secretion	[165]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Affects Expression	[166]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Secretion	[167]
Alpha-crystallin B chain (CRYAB)	OTY4JGYU	CRYAB_HUMAN	Affects Expression	[132]
Prelamin-A/C (LMNA)	OT3SG7ZR	LMNA_HUMAN	Affects Expression	[132]
Fibrinogen gamma chain (FGG)	OT5BJSEX	FIBG_HUMAN	Affects Expression	[132]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[168]
Fibronectin (FN1)	OTB5ZN4Q	FINC_HUMAN	Decreases Expression	[169]
Serotransferrin (TF)	OT41PEMS	TRFE_HUMAN	Affects Expression	[132]
Ferritin light chain (FTL)	OTYQA8A6	FRIL_HUMAN	Affects Expression	[132]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Affects Expression	[132]
Trefoil factor 1 (TFF1)	OTCYQH4F	TFF1_HUMAN	Increases Expression	[170]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Decreases Expression	[171]
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)	OTBPMIMW	G3P_HUMAN	Affects Expression	[132]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[157]
Heat shock protein beta-1 (HSPB1)	OTHFZ8ED	HSPB1_HUMAN	Affects Expression	[132]
Insulin-like growth factor I (IGF1)	OTIIZR61	IGF1_HUMAN	Decreases Secretion	[172]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Affects Expression	[132]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Affects Expression	[166]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Decreases Expression	[173]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[174]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[175]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Expression	[176]
Beta-casein (CSN2)	OT22C0PD	CASB_HUMAN	Increases Expression	[177]
Insulin receptor (INSR)	OTTY341H	INSR_HUMAN	Increases Phosphorylation	[178]
Gelsolin (GSN)	OT4KS2UU	GELS_HUMAN	Increases Expression	[179]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[180]
ATP synthase subunit beta, mitochondrial (ATP5F1B)	OTLFZUQK	ATPB_HUMAN	Decreases Expression	[181]
Alpha-enolase (ENO1)	OTB1KWJS	ENOA_HUMAN	Affects Expression	[132]
Tropomyosin alpha-3 chain (TPM3)	OT5RU5G6	TPM3_HUMAN	Decreases Expression	[182]
Lipoprotein lipase (LPL)	OTTW0267	LIPL_HUMAN	Increases Expression	[183]
Protein disulfide-isomerase (P4HB)	OTTYNYPF	PDIA1_HUMAN	Affects Expression	[132]
Annexin A2 (ANXA2)	OTFNS0CC	ANXA2_HUMAN	Affects Expression	[132]
Transcription factor Sp1 (SP1)	OTISPT4X	SP1_HUMAN	Decreases Expression	[169]
Integrin alpha-IIb (ITGA2B)	OT4Y17PY	ITA2B_HUMAN	Affects Expression	[132]
Integrin alpha-5 (ITGA5)	OT3RCI67	ITA5_HUMAN	Increases Expression	[135]
Galectin-1 (LGALS1)	OT8LDFWR	LEG1_HUMAN	Affects Expression	[132]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[184]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[185]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Increases Expression	[186]
Hepatic triacylglycerol lipase (LIPC)	OTZY5SC9	LIPC_HUMAN	Increases Expression	[162]
Lysosome-associated membrane glycoprotein 1 (LAMP1)	OTYE92QY	LAMP1_HUMAN	Increases Expression	[180]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Increases Expression	[157]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[187]
Collagen alpha-1(VI) chain (COL6A1)	OTYKSCOB	CO6A1_HUMAN	Affects Expression	[132]
Collagen alpha-2(VI) chain (COL6A2)	OTQC6PPO	CO6A2_HUMAN	Affects Expression	[132]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[179]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Decreases Response To Substance	[188]
Beta-3 adrenergic receptor (ADRB3)	OTPMG4V7	ADRB3_HUMAN	Decreases Expression	[189]
Hepatocyte growth factor (HGF)	OTGHUA23	HGF_HUMAN	Increases Expression	[190]
Nidogen-1 (NID1)	OTKLBLS6	NID1_HUMAN	Affects Expression	[132]
Endoplasmin (HSP90B1)	OT02XLBR	ENPL_HUMAN	Affects Expression	[132]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Decreases Expression	[191]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4)	OTJZG0LD	GLUT4_HUMAN	Increases Expression	[192]
Insulin-degrading enzyme (IDE)	OT5GQTJ5	IDE_HUMAN	Increases Expression	[193]
Fatty acid-binding protein, adipocyte (FABP4)	OT3DKFOU	FABP4_HUMAN	Increases Expression	[194]
P-selectin (SELP)	OTWR90PK	LYAM3_HUMAN	Decreases Expression	[195]
Cyclic AMP-responsive element-binding protein 1 (CREB1)	OT1MDLA1	CREB1_HUMAN	Decreases Phosphorylation	[169]
Platelet endothelial cell adhesion molecule (PECAM1)	OTXOM4D9	PECA1_HUMAN	Decreases Expression	[196]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3)	OTA6HYBA	GBB3_HUMAN	Affects Expression	[132]
E-selectin (SELE)	OT33RZWY	LYAM2_HUMAN	Decreases Expression	[168]
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)	OTPGAU0U	AT2A2_HUMAN	Increases Expression	[197]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Increases Expression	[198]
Neutrophil cytosol factor 2 (NCF2)	OTAUW7L2	NCF2_HUMAN	Decreases Expression	[199]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[191]
Filamin-A (FLNA)	OTYZ9JXM	FLNA_HUMAN	Affects Expression	[132]
Thromboxane A2 receptor (TBXA2R)	OT9CIHQ5	TA2R_HUMAN	Decreases Expression	[200]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Expression	[201]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Decreases Phosphorylation	[202]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[179]
Endothelin receptor type B (EDNRB)	OTLLZV3P	EDNRB_HUMAN	Increases Expression	[203]
Cyclin-C (CCNC)	OTMVK4K4	CCNC_HUMAN	Decreases Expression	[157]
G1/S-specific cyclin-E1 (CCNE1)	OTLD7UID	CCNE1_HUMAN	Decreases Expression	[191]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[191]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[179]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Decreases Phosphorylation	[184]
Moesin (MSN)	OTZJ4J6G	MOES_HUMAN	Affects Expression	[132]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[204]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1)	OT5BZ1J9	P85A_HUMAN	Increases Expression	[134]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[204]
Retinoic acid receptor RXR-beta (RXRB)	OTNPDXG2	RXRB_HUMAN	Affects Binding	[205]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Increases Phosphorylation	[206]
Protein disulfide-isomerase A3 (PDIA3)	OTHPQ0Q3	PDIA3_HUMAN	Affects Expression	[132]
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PPP2R1A)	OTYA3GB4	2AAA_HUMAN	Increases Expression	[157]
G1/S-specific cyclin-D2 (CCND2)	OTDULQF9	CCND2_HUMAN	Decreases Expression	[187]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Decreases Expression	[191]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[207]
Peroxiredoxin-2 (PRDX2)	OTLWCY9T	PRDX2_HUMAN	Affects Expression	[132]
C-C chemokine receptor type 7 (CCR7)	OTHFUOYE	CCR7_HUMAN	Decreases Expression	[208]
T-lymphocyte activation antigen CD80 (CD80)	OTJBLUQE	CD80_HUMAN	Decreases Expression	[208]
Polycomb complex protein BMI-1 (BMI1)	OTROVLJ0	BMI1_HUMAN	Decreases Expression	[196]
Nitric oxide synthase, inducible (NOS2)	OTKKIOJ1	NOS2_HUMAN	Decreases Expression	[167]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[209]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1)	OTNWEJ5Y	PCKGC_HUMAN	Increases Expression	[210]
Insulin receptor substrate 1 (IRS1)	OTNO82CU	IRS1_HUMAN	Increases Phosphorylation	[178]
Myosin-9 (MYH9)	OT94Z706	MYH9_HUMAN	Affects Expression	[132]
Tumor necrosis factor receptor superfamily member 3 (LTBR)	OT2HVZGV	TNR3_HUMAN	Increases Expression	[157]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Expression	[177]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Decreases Expression	[167]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[157]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Decreases Expression	[134]
Neuroblastoma suppressor of tumorigenicity 1 (NBL1)	OTT37U4O	NBL1_HUMAN	Increases Expression	[157]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Increases Expression	[208]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Decreases Expression	[157]
Nicotinamide phosphoribosyltransferase (NAMPT)	OTVJR3GL	NAMPT_HUMAN	Affects Expression	[211]
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)	OT1H0ZXC	ACHA4_HUMAN	Decreases Expression	[204]
ATP-binding cassette sub-family G member 1 (ABCG1)	OT5BG6MK	ABCG1_HUMAN	Increases Expression	[212]
Proliferation marker protein Ki-67 (MKI67)	OTA8N1QI	KI67_HUMAN	Decreases Expression	[196]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[187]
Stromal cell-derived factor 1 (CXCL12)	OT2QX5LL	SDF1_HUMAN	Decreases Response To Substance	[188]
Retinoic acid receptor RXR-gamma (RXRG)	OT254B09	RXRG_HUMAN	Affects Binding	[205]
CX3C chemokine receptor 1 (CX3CR1)	OTIM9XT8	CX3C1_HUMAN	Decreases Expression	[213]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[177]
Caspase-4 (CASP4)	OTVQTV1L	CASP4_HUMAN	Decreases Expression	[157]
Steroidogenic acute regulatory protein, mitochondrial (STAR)	OTFEZ5AI	STAR_HUMAN	Increases Expression	[165]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Increases Expression	[214]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2)	OTAKUO27	ACOT2_HUMAN	Increases Expression	[159]
Tuberin (TSC2)	OT47LWI9	TSC2_HUMAN	Increases Phosphorylation	[202]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[215]
Cyclin-dependent kinase 7 (CDK7)	OTAO19PQ	CDK7_HUMAN	Decreases Expression	[157]
Death-associated protein 1 (DAP)	OT5YLL7E	DAP1_HUMAN	Increases Expression	[157]
Small ribosomal subunit protein mS29 (DAP3)	OTNPEZYM	RT29_HUMAN	Decreases Expression	[157]
Caveolin-2 (CAV2)	OT1FGRQX	CAV2_HUMAN	Increases Expression	[177]
Hexokinase-2 (HK2)	OTC0GCQO	HXK2_HUMAN	Increases Expression	[216]
Microsomal triglyceride transfer protein large subunit (MTTP)	OTNUVSDT	MTP_HUMAN	Increases Expression	[159]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[217]
Laminin subunit beta-2 (LAMB2)	OT71OI2Y	LAMB2_HUMAN	Affects Expression	[132]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Expression	[218]
GTP-binding nuclear protein Ran (RAN)	OT2TER5M	RAN_HUMAN	Decreases Expression	[157]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1)	OTLL7L74	GBB1_HUMAN	Affects Expression	[132]
Tropomyosin alpha-4 chain (TPM4)	OTN4YLYR	TPM4_HUMAN	Affects Expression	[132]
Fractalkine (CX3CL1)	OTPLGI0E	X3CL1_HUMAN	Affects Localization	[213]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Increases Activity	[219]
Protein delta homolog 1 (DLK1)	OTE1VLNB	DLK1_HUMAN	Decreases Expression	[220]
Fatty acid-binding protein 5 (FABP5)	OTNM186C	FABP5_HUMAN	Affects Expression	[132]
Caveolin-1 (CAV1)	OTEZUR1L	CAV1_HUMAN	Increases Expression	[221]
Peroxisome proliferator-activated receptor delta (PPARD)	OTI4WTOP	PPARD_HUMAN	Increases Expression	[222]
Focal adhesion kinase 1 (PTK2)	OT3Q1JDY	FAK1_HUMAN	Decreases Phosphorylation	[223]
Hormone-sensitive lipase (LIPE)	OTMMVJ8A	LIPS_HUMAN	Increases Expression	[162]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[157]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Increases Expression	[157]
Peroxisome proliferator-activated receptor alpha (PPARA)	OTK095PP	PPARA_HUMAN	Affects Binding	[224]
Prolow-density lipoprotein receptor-related protein 1 (LRP1)	OTHTEH4G	LRP1_HUMAN	Increases Expression	[225]
Peroxisomal bifunctional enzyme (EHHADH)	OTBAAHL5	ECHP_HUMAN	Increases Expression	[159]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[221]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[226]
Runt-related transcription factor 2 (RUNX2)	OT97RQQM	RUNX2_HUMAN	Decreases Expression	[227]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Decreases Expression	[174]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Increases Expression	[180]
LIM and SH3 domain protein 1 (LASP1)	OT2QIDCL	LASP1_HUMAN	Affects Expression	[132]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Expression	[159]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1)	OTM0A0DY	ACOX1_HUMAN	Increases Expression	[162]
Mediator of RNA polymerase II transcription subunit 1 (MED1)	OTOO24C4	MED1_HUMAN	Affects Binding	[228]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Increases Expression	[229]
Transcription factor E2F4 (E2F4)	OTB3JFH4	E2F4_HUMAN	Decreases Expression	[230]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[157]
kinase isozyme 4, mitochondrial (PDK4)	OTCMHMBZ	PDK4_HUMAN	Increases Expression	[216]
Caveolae-associated protein 1 (CAVIN1)	OTFO915U	CAVN1_HUMAN	Affects Expression	[132]
Long-chain fatty acid transport protein 1 (SLC27A1)	OTK03OZN	S27A1_HUMAN	Decreases Expression	[216]
Adiponectin receptor protein 2 (ADIPOR2)	OT2HDTL8	PAQR2_HUMAN	Increases Expression	[231]
Ferritin, mitochondrial (FTMT)	OTIUX6XG	FTMT_HUMAN	Affects Expression	[132]
Carnitine O-palmitoyltransferase 1, muscle isoform (CPT1B)	OTDNRW37	CPT1B_HUMAN	Increases Expression	[232]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[157]
Adiponectin receptor protein 1 (ADIPOR1)	OT65ZFZN	PAQR1_HUMAN	Affects Expression	[233]
Necdin (NDN)	OTYBYJ82	NECD_HUMAN	Increases Expression	[230]
Retinoic acid receptor responder protein 2 (RARRES2)	OT1BJE8K	RARR2_HUMAN	Decreases Expression	[234]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1)	OT50NR57	PINK1_HUMAN	Increases Expression	[235]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Decreases Expression	[45]
COMM domain-containing protein 5 (COMMD5)	OT6R7DXN	COMD5_HUMAN	Increases Expression	[236]
Ras-related protein Rab-1B (RAB1B)	OTAFCUAS	RAB1B_HUMAN	Increases Expression	[157]
Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM)	OTR1XD9B	GPAT1_HUMAN	Increases Expression	[159]
Chorion-specific transcription factor GCMa (GCM1)	OT5CPAUT	GCM1_HUMAN	Increases Expression	[140]
Fibroblast growth factor 21 (FGF21)	OT3RXVRD	FGF21_HUMAN	Increases Expression	[237]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)	OTHCDQ22	PRGC1_HUMAN	Increases Expression	[192]
Probable ATP-dependent RNA helicase DDX41 (DDX41)	OT6KEIHP	DDX41_HUMAN	Increases Expression	[157]
Cyclin-L1 (CCNL1)	OTAJSS3D	CCNL1_HUMAN	Decreases Expression	[157]
Anaphase-promoting complex subunit 10 (ANAPC10)	OTM03SME	APC10_HUMAN	Decreases Expression	[157]
Insulin receptor substrate 2 (IRS2)	OT46MJBE	IRS2_HUMAN	Increases Expression	[238]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Metabolism	[239]
Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2)	OTK5T6HZ	NFAC2_HUMAN	Affects Response To Substance	[240]
Phosphatidate phosphatase LPIN1 (LPIN1)	OTQ75KF2	LPIN1_HUMAN	Increases Response To Substance	[241]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Pre-diabetes	DCLMIB8	N. A.	Phase 1	[242]

References

• [1] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [2] Simvastatin FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2955).
• [4] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [5] Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008 Mar;51(3):267-73. doi: 10.1097/FJC.0b013e3181624b44.
• [6] Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
• [7] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
• [8] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [9] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [10] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [11] A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
• [12] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [13] Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
• [14] In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
• [15] Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
• [16] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [17] Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
• [18] Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2007 Jan;47(1):87-93. doi: 10.1177/0091270006295063.
• [19] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [20] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [21] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [22] Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007 Apr;55(4):310-7. doi: 10.1016/j.phrs.2006.12.009. Epub 2007 Jan 14.
• [23] Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
• [24] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [25] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [26] The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
• [27] Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
• [28] Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008 May;198(1):198-207.
• [29] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [30] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [31] Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Cardiovasc Res. 2008 Oct 1;80(1):151-8.
• [32] Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost. 2008 Jul;100(1):119-26.
• [33] High ambient glucose augments angiotensin II-induced proinflammatory gene mRNA expression in human mesangial cells: effects of valsartan and simvastatin. Am J Nephrol. 2009;30(2):99-111.
• [34] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [35] Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
• [36] Simvastatin modulates the Alzheimer's disease-related gene seladin-1. J Alzheimers Dis. 2012;28(2):297-301.
• [37] Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells. J Clin Endocrinol Metab. 2013 Mar;98(3):E455-62.
• [38] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [39] Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
• [40] [Effect of simvastatin on the function of MG63 cell line]. Shanghai Kou Qiang Yi Xue. 2010 Dec;19(6):658-62.
• [41] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [42] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [43] Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol. 2007 Feb 15;178(4):2507-16. doi: 10.4049/jimmunol.178.4.2507.
• [44] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [45] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [46] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [47] Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 2006 Jul;70(1):177-86. doi: 10.1038/sj.ki.5001515. Epub 2006 May 17.
• [48] Cholesterol increases protein levels of the E3 ligase MARCH6 and thereby stimulates protein degradation. J Biol Chem. 2019 Feb 15;294(7):2436-2448. doi: 10.1074/jbc.RA118.005069. Epub 2018 Dec 13.
• [49] Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis. 2011 Jul 5;10:112. doi: 10.1186/1476-511X-10-112.
• [50] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [51] Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004 May;30(5):662-70. doi: 10.1165/rcmb.2003-0267OC. Epub 2003 Nov 20.
• [52] Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int. 2002 Nov;62(5):1611-9. doi: 10.1046/j.1523-1755.2002.00601.x.
• [53] Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008 Jun;26(6):1147-55. doi: 10.1097/HJH.0b013e3282f97dde.
• [54] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [55] Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res. 1994 Jun;85(6):633-8. doi: 10.1111/j.1349-7006.1994.tb02406.x.
• [56] Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int. 1993 Sep;44(3):503-8. doi: 10.1038/ki.1993.274.
• [57] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [58] Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol. 2007 Aug;43(2):168-76. doi: 10.1016/j.yjmcc.2007.05.006. Epub 2007 May 18.
• [59] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [60] Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
• [61] A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One. 2006 Dec 20;1(1):e97. doi: 10.1371/journal.pone.0000097.
• [62] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [63] Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
• [64] Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. J Hepatol. 1999 May;30(5):904-10. doi: 10.1016/s0168-8278(99)80146-9.
• [65] The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005 Jun;20(3):438-44. doi: 10.3346/jkms.2005.20.3.438.
• [66] Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007 May;27(5):1043-9. doi: 10.1161/ATVBAHA.107.139881. Epub 2007 Feb 15.
• [67] Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009 May;21(5):1317-22. doi: 10.3892/or_00000357.
• [68] Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1999 Sep 15;84(6):655-9. doi: 10.1016/s0002-9149(99)00411-7.
• [69] Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
• [70] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [71] Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
• [72] Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):397-403. doi: 10.1161/01.ATV.0000059384.34874.F0. Epub 2003 Jan 30.
• [73] Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
• [74] Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
• [75] Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
• [76] [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;39(1):72-5.
• [77] Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int. 2003 Jun;63(6):2065-74. doi: 10.1046/j.1523-1755.2003.t01-2-00004.x.
• [78] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [79] [Simvastatin-induced apoptosis of K562 cells is mediated by endoplasmic reticulum stress]. Yao Xue Xue Bao. 2008 Apr;43(4):371-7.
• [80] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [81] Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. 2008 Jul 25;372(2):356-61. doi: 10.1016/j.bbrc.2008.05.043. Epub 2008 May 19.
• [82] Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
• [83] The role of simvastatin in the osteogenesis of injectable tissue-engineered bone based on human adipose-derived stromal cells and platelet-rich plasma. Biomaterials. 2010 Jul;31(20):5325-35. doi: 10.1016/j.biomaterials.2010.03.037. Epub 2010 Apr 9.
• [84] Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010 Sep 11;41(1):118-24. doi: 10.1016/j.ejps.2010.05.021. Epub 2010 Jun 8.
• [85] Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol. 2007 Aug;58 Suppl 3:141-8.
• [86] Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011 Jan;25(1):41-7.
• [87] Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
• [88] Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol. 1999 Summer;6(2):85-90.
• [89] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [90] Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun. 2000 May 19;271(3):688-92. doi: 10.1006/bbrc.2000.2697.
• [91] Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Transplant Proc. 2006 Nov;38(9):2899-904. doi: 10.1016/j.transproceed.2006.08.136.
• [92] Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000 May 15;69(9):1830-6. doi: 10.1097/00007890-200005150-00017.
• [93] Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004 Apr;94(4):403-9. doi: 10.1254/jphs.94.403.
• [94] Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol. 2010 Aug;161(2):298-305. doi: 10.1111/j.1365-2249.2010.04170.x. Epub 2010 May 18.
• [95] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [96] Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab. 2003 Nov;88(11):5341-7. doi: 10.1210/jc.2003-030724.
• [97] Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction. J Int Med Res. 2009 May-Jun;37(3):601-10. doi: 10.1177/147323000903700302.
• [98] Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2083-9. doi: 10.1161/01.ATV.0000096207.01487.36. Epub 2003 Sep 18.
• [99] Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 Oct 15;172(8):987-93. doi: 10.1164/rccm.200501-041OC. Epub 2005 Jul 7.
• [100] Temporal gene expression analysis of human coronary artery endothelial cells treated with Simvastatin. Gene Expr. 2008;14(4):229-39. doi: 10.3727/105221608786883834.
• [101] Angiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatin. J Cardiovasc Pharmacol. 2007 May;49(5):299-305. doi: 10.1097/FJC.0b013e31803d35ce.
• [102] Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005 Feb 28;133(2-3):197-203. doi: 10.1016/j.psychres.2004.11.005.
• [103] Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res. 2008;122(2):191-202. doi: 10.1016/j.thromres.2007.09.017. Epub 2007 Nov 26.
• [104] Mechanism of simvastatin-induced K562 cell apoptosis. Pharmacology. 2009;84(4):191-5. doi: 10.1159/000235907. Epub 2009 Sep 2.
• [105] Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009 Aug;33(2):107-14.
• [106] HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005 Mar 22;111(11):1439-47. doi: 10.1161/01.CIR.0000158484.18024.1F.
• [107] Molecular mechanisms underlying the inhibition of IFN--induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem. 2011 Feb;112(2):675-83. doi: 10.1002/jcb.22976.
• [108] [Effects of simvastatin on proliferation and apoptosis of acute monocytic leukemia cell line SHI-1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Jun;19(3):612-6.
• [109] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [110] [Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome]. Nan Fang Yi Ke Da Xue Xue Bao. 2008 Mar;28(3):475-7.
• [111] Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
• [112] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [113] Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
• [114] Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. Cancer Res Commun. 2023 Dec 8;3(12):2497-2509. doi: 10.1158/2767-9764.CRC-23-0350.
• [115] HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 2005 Mar;19(3):476-8. doi: 10.1096/fj.04-2745fje. Epub 2004 Dec 29.
• [116] Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010 Apr 15;79(8):1200-9. doi: 10.1016/j.bcp.2009.12.007. Epub 2009 Dec 14.
• [117] Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Mol Neurobiol. 2010 Jun;41(2-3):384-91. doi: 10.1007/s12035-010-8122-8. Epub 2010 Apr 6.
• [118] Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochem Biophys Res Commun. 2006 Jan 6;339(1):59-64. doi: 10.1016/j.bbrc.2005.10.187. Epub 2005 Nov 8.
• [119] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [120] Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.
• [121] Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol. 2008 Nov 15;181(10):7332-40. doi: 10.4049/jimmunol.181.10.7332.
• [122] Simvastatin induces the odontogenic differentiation of human dental pulp stem cells in vitro and in vivo. J Endod. 2009 Mar;35(3):367-72. doi: 10.1016/j.joen.2008.11.024.
• [123] A beneficial effect of simvastatin on DNA damage in 242T allele of the NADPH oxidase p22phox in hypercholesterolemic patients. Clin Chim Acta. 2005 Oct;360(1-2):46-51. doi: 10.1016/j.cccn.2005.04.001.
• [124] Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007 Sep;36(3):329-35. doi: 10.1002/mus.20871.
• [125] Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men. Diabetes Res Clin Pract. 2003 Dec;62(3):169-75. doi: 10.1016/s0168-8227(03)00163-3.
• [126] NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
• [127] Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J. 2005;5(6):359-64. doi: 10.1038/sj.tpj.6500334.
• [128] Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43. doi: 10.1016/j.jacc.2007.05.057.
• [129] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [130] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [131] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [132] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [133] Rosiglitazone induces the unfolded protein response, but has no significant effect on cell viability, in monocytic and vascular smooth muscle cells. Biochem Biophys Res Commun. 2010 Oct 1;400(4):689-95. doi: 10.1016/j.bbrc.2010.08.129. Epub 2010 Sep 9.
• [134] Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun. 1999 Nov;265(1):265-71. doi: 10.1006/bbrc.1999.1657.
• [135] All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur J Haematol. 2009 Sep;83(3):191-202. doi: 10.1111/j.1600-0609.2009.01277.x. Epub 2009 May 8.
• [136] ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
• [137] Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
• [138] Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
• [139] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [140] Regulation of the placental BCRP transporter by PPAR gamma. J Biochem Mol Toxicol. 2017 May;31(5):10.1002/jbt.21880. doi: 10.1002/jbt.21880. Epub 2016 Nov 23.
• [141] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [142] Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
• [143] The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol. 2004 Aug;25(2):493-502.
• [144] Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun. 2004 Oct 22;323(3):782-8.
• [145] Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol. 2005 Oct;19(10):2502-16.
• [146] Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
• [147] Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab. 2007 Feb;92(2):720-4.
• [148] Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. Mol Pharmacol. 2007 Sep;72(3):674-85.
• [149] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [150] Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Aug;37(8):739-45.
• [151] Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS Med Chem Lett. 2011 Oct 15;3(1):39-42.
• [152] Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos. 2013 Dec;41(12):2087-94.
• [153] PPARgama activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol. 2014 Mar;253:16-27.
• [154] Rosiglitazone inhibits chlorpyrifos-induced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells. Toxicol Appl Pharmacol. 2014 Jul 15;278(2):159-71.
• [155] A comprehensive evaluation of anti-diabetic drugs on nuclear receptor PXR platform. Toxicol In Vitro. 2019 Oct;60:347-358.
• [156] Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes. 2005 May;54(5):1379-84. doi: 10.2337/diabetes.54.5.1379.
• [157] Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007 Jun;14(2):305-15. doi: 10.1677/ERC-06-0003.
• [158] Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med. 2008 Mar 15;44(6):1055-68. doi: 10.1016/j.freeradbiomed.2007.12.001. Epub 2007 Dec 8.
• [159] Replacement per- and polyfluoroalkyl substances (PFAS) are potent modulators of lipogenic and drug metabolizing gene expression signatures in primary human hepatocytes. Toxicol Appl Pharmacol. 2022 May 1;442:115991. doi: 10.1016/j.taap.2022.115991. Epub 2022 Mar 23.
• [160] Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Anticancer Res. 2008 Mar-Apr;28(2A):895-906.
• [161] [Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Mar;40(2):217-22.
• [162] In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. PPAR Res. 2012;2012:546548. doi: 10.1155/2012/546548. Epub 2012 Oct 22.
• [163] [Effect of Rosiglitazone on the proliferation and the production of transforming growth factor-beta 1 in cultured human Tenon' s capsule fibroblasts]. Zhonghua Yan Ke Za Zhi. 2008 May;44(5):413-7.
• [164] PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun. 2008 Feb 22;366(4):1096-101. doi: 10.1016/j.bbrc.2007.12.088. Epub 2007 Dec 26.
• [165] Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol. 2009 Dec 9;7:147. doi: 10.1186/1477-7827-7-147.
• [166] [Effect of rosiglitazone on the expression of T-bet/GATA-3 in T lymphocytes in patients with acute asthma]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):116-20.
• [167] The PPAR-dependent effect of flavonoid luteolin against damage induced by the chemotherapeutic irinotecan in human intestinal cells. Chem Biol Interact. 2022 Jan 5;351:109712. doi: 10.1016/j.cbi.2021.109712. Epub 2021 Oct 23.
• [168] Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1804-9. doi: 10.1161/01.ATV.0000176192.16951.9a. Epub 2005 Jul 7.
• [169] Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L419-28. doi: 10.1152/ajplung.00002.2005. Epub 2005 May 20.
• [170] Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat. 2008 Mar;108(1):23-33. doi: 10.1007/s10549-007-9575-y. Epub 2007 Apr 24.
• [171] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [172] Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology. 2007 Feb;148(2):903-11. doi: 10.1210/en.2006-1121. Epub 2006 Nov 22.
• [173] Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1577-81. doi: 10.1161/01.atv.19.6.1577.
• [174] Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006 May;29(5):1071-6. doi: 10.2337/diacare.2951071.
• [175] PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E174-83. doi: 10.1152/ajpendo.90632.2008. Epub 2009 May 5.
• [176] VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092. doi: 10.1038/s41598-018-34259-0.
• [177] Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol. 2006 Aug 28;72(5):530-40. doi: 10.1016/j.bcp.2006.05.009. Epub 2006 Jun 27.
• [178] Methamphetamine exposure upregulates the amyloid precursor protein and hyperphosphorylated tau expression: The roles of insulin signaling in SH-SY5Y cell line. J Toxicol Sci. 2019;44(7):493-503. doi: 10.2131/jts.44.493.
• [179] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [180] Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp Cell Res. 2011 Jun 10;317(10):1397-410. doi: 10.1016/j.yexcr.2011.02.014. Epub 2011 Mar 3.
• [181] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [182] Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol. 2009 Jul;76(1):183-91. doi: 10.1124/mol.109.056028. Epub 2009 Apr 15.
• [183] Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. Eur J Clin Invest. 2003 Jul;33(7):574-81. doi: 10.1046/j.1365-2362.2003.01178.x.
• [184] Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem. 2001 Aug 17;276(33):31059-66. doi: 10.1074/jbc.M104141200. Epub 2001 Jun 7.
• [185] Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett. 2009 Mar 18;275(2):247-55. doi: 10.1016/j.canlet.2008.10.023. Epub 2008 Dec 3.
• [186] Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. Toxicol Sci. 2005 Feb;83(2):293-302. doi: 10.1093/toxsci/kfi022. Epub 2004 Nov 3.
• [187] Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):523-30. doi: 10.1111/j.1742-7843.2010.00539.x. Epub 2010 Feb 22.
• [188] Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension. 2008 Feb;51(2):259-66. doi: 10.1161/HYPERTENSIONAHA.107.099028. Epub 2007 Dec 24.
• [189] Impact of rosiglitazone on the expression of beta3-AR in the stable cell lines expressed beta3-AR gene. Clin Chem Lab Med. 2007;45(11):1511-6. doi: 10.1515/CCLM.2007.315.
• [190] Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR- and subsequent expression of HGF in colons. Toxicol Appl Pharmacol. 2018 Mar 15;343:1-15. doi: 10.1016/j.taap.2018.02.001. Epub 2018 Feb 3.
• [191] Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
• [192] Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia. 2005 Jun;48(6):1173-9. doi: 10.1007/s00125-005-1741-3. Epub 2005 Apr 30.
• [193] Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury. Acta Pharmacol Sin. 2011 Aug;32(8):991-8. doi: 10.1038/aps.2011.81. Epub 2011 Jul 18.
• [194] Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. J Pharmacol Exp Ther. 2004 Nov;311(2):467-75. doi: 10.1124/jpet.104.068254. Epub 2004 Jul 23.
• [195] Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis. 2008 Jul;199(1):55-64. doi: 10.1016/j.atherosclerosis.2007.10.038. Epub 2008 Feb 21.
• [196] Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer. 2010 Feb 18;17(1):169-77. doi: 10.1677/ERC-09-0170. Print 2010 Mar.
• [197] Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells. Biochem Biophys Res Commun. 2008 Feb 1;366(1):149-55. doi: 10.1016/j.bbrc.2007.11.095. Epub 2007 Nov 29.
• [198] Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem Pharmacol. 2004 Jul 1;68(1):155-63. doi: 10.1016/j.bcp.2004.03.009.
• [199] Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol. 2007 Feb;170(2):722-32. doi: 10.2353/ajpath.2007.060651.
• [200] Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. Biochem Pharmacol. 2006 Apr 28;71(9):1308-23. doi: 10.1016/j.bcp.2006.01.011. Epub 2006 Feb 23.
• [201] Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine. 2007 Sep;39(3):184-91. doi: 10.1016/j.cyto.2007.07.191. Epub 2007 Sep 5.
• [202] Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2. PPAR Res. 2007;2007:29632. doi: 10.1155/2007/29632.
• [203] Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension. 2010 Jul;56(1):129-35. doi: 10.1161/HYPERTENSIONAHA.110.150375. Epub 2010 Jun 1.
• [204] Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals. Mol Cancer Ther. 2009 Jan;8(1):110-8. doi: 10.1158/1535-7163.MCT-08-0719.
• [205] Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
• [206] Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells. J Biol Chem. 2006 May 12;281(19):13503-13512. doi: 10.1074/jbc.M510357200. Epub 2006 Mar 9.
• [207] Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer. 2006 May 15;118(10):2390-8. doi: 10.1002/ijc.21799.
• [208] 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J Immunol. 2007 May 15;178(10):6130-9. doi: 10.4049/jimmunol.178.10.6130.
• [209] [Effects of rosiglitazone on the Hep-2 cell proliferation, cell cycle and COX-2 expression]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Apr;24(7):315-7.
• [210] Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes. Biochimie. 2003 Dec;85(12):1257-64. doi: 10.1016/j.biochi.2003.10.016.
• [211] Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis. Mol Hum Reprod. 2013 May;19(5):313-26. doi: 10.1093/molehr/gat002. Epub 2013 Jan 11.
• [212] 2,2',4,4'-Tetrabromodiphenyl Ether (PBDE 47) Selectively Stimulates Proatherogenic PPAR Signatures in Human THP-1 Macrophages to Contribute to Foam Cell Formation. Chem Res Toxicol. 2022 Jun 20;35(6):1023-1035. doi: 10.1021/acs.chemrestox.2c00043. Epub 2022 May 16.
• [213] Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol. 2010 Feb;44(2):135-42. doi: 10.1677/JME-09-0090. Epub 2009 Oct 22.
• [214] Effects of Perinatal Exposure to Dibutyltin Chloride on Fat and Glucose Metabolism in Mice, and Molecular Mechanisms, in Vitro. Environ Health Perspect. 2018 May 21;126(5):057006. doi: 10.1289/EHP3030. eCollection 2018 May.
• [215] Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice. Toxicol Appl Pharmacol. 2015 May 15;285(1):61-70. doi: 10.1016/j.taap.2015.03.011. Epub 2015 Mar 18.
• [216] The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005 Jan;48(1):83-95. doi: 10.1007/s00125-004-1619-9. Epub 2004 Dec 24.
• [217] Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007 Jun;28(6):879-87. doi: 10.1111/j.1745-7254.2007.00571.x.
• [218] PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun. 2003 Apr 11;303(3):782-7. doi: 10.1016/s0006-291x(03)00418-2.
• [219] Tributyltin and triphenyltin induce 11-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor . Toxicol Lett. 2020 Apr 1;322:39-49. doi: 10.1016/j.toxlet.2020.01.001. Epub 2020 Jan 9.
• [220] Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism. Environ Health Perspect. 2012 Jul;120(7):984-9. doi: 10.1289/ehp.1205063. Epub 2012 May 25.
• [221] Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res. 2004 Nov;45(11):2015-24. doi: 10.1194/jlr.M400049-JLR200. Epub 2004 Aug 16.
• [222] Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond). 2007 Aug;31(8):1302-10. doi: 10.1038/sj.ijo.0803567. Epub 2007 Feb 20.
• [223] PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther. 2006 Aug;5(8):1008-14. doi: 10.4161/cbt.5.8.2887. Epub 2006 Aug 7.
• [224] Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. doi: 10.1006/bbrc.2001.6141.
• [225] The effect of rosiglitazone on LRP1 expression and amyloid uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2012 Feb;15(1):135-42. doi: 10.1017/S1461145711001611. Epub 2011 Nov 1.
• [226] Involvement of peroxisome proliferator-activated receptor gamma (PPAR) and autophagic pathways in the mechanism of action of the tris(2,3-dibromopropyl) isocyanurate (TDBP-TAZTO or TBC) flame retardant in the lung adenocarcinoma (A549) cells in vitro. J Appl Toxicol. 2023 Sep;43(9):1358-1367. doi: 10.1002/jat.4470. Epub 2023 Mar 31.
• [227] Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 2007 Oct;30(9):RC26-30. doi: 10.1007/BF03350807.
• [228] Selective Tissue Distribution Mediates Tissue-Dependent PPAR Activation and Insulin Sensitization by INT131, a Selective PPAR Modulator. Front Pharmacol. 2017 May 30;8:317. doi: 10.3389/fphar.2017.00317. eCollection 2017.
• [229] Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004 Aug;53(8):2169-76. doi: 10.2337/diabetes.53.8.2169.
• [230] Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue. Diabetes. 2006 Mar;55(3):640-50. doi: 10.2337/diabetes.55.03.06.db05-1015.
• [231] Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Diabetologia. 2006 Jun;49(6):1303-10. doi: 10.1007/s00125-006-0228-1. Epub 2006 Apr 12.
• [232] Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance. Patholog Res Int. 2011 Apr 12;2011:736425. doi: 10.4061/2011/736425.
• [233] Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia. 2005 Aug;48(8):1585-9. doi: 10.1007/s00125-005-1835-y. Epub 2005 Jul 1.
• [234] Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol Lett. 2018 Jul;291:61-69. doi: 10.1016/j.toxlet.2018.04.004. Epub 2018 Apr 10.
• [235] PPAR- activation attenuates deltamethrin-induced apoptosis by regulating cytosolic PINK1 and inhibiting mitochondrial dysfunction. Toxicol Lett. 2016 Oct 17;260:8-17. doi: 10.1016/j.toxlet.2016.08.016. Epub 2016 Aug 21.
• [236] Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncol Rep. 2008 Nov;20(5):1093-7.
• [237] Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol Pharm Bull. 2011;34(7):1120-1. doi: 10.1248/bpb.34.1120.
• [238] Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab. 2005 Dec;90(12):6678-86. doi: 10.1210/jc.2005-0079. Epub 2005 Oct 4.
• [239] Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metab Dispos. 2011 Apr;39(4):711-6. doi: 10.1124/dmd.110.035899. Epub 2011 Jan 18.
• [240] Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care. 2010 Oct;33(10):2250-3. doi: 10.2337/dc10-0452. Epub 2010 Jul 13.
• [241] LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients. Mol Genet Metab. 2008 Sep-Oct;95(1-2):96-100. doi: 10.1016/j.ymgme.2008.06.011. Epub 2008 Aug 9.
• [242] ClinicalTrials.gov (NCT00831129) A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs